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TARGETING EPIGENETIC REGULATORS FOR THE TREATMENT OF DIFFUSE 
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Small-molecule inhibitors of the histone methyltransferase EZH2 hold great promise for the 
treatment of Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL). 
Compared to a 60% Objective Response Rate (ORR) in Phase I clinical trials, Phase II trial 
results for the EZH2 inhibitor EPZ-6438 reported an attenuation of response. Mechanisms 
contributing to lymphoma cell survival and growth after EZH2 ablation are poorly studied. In 
EZH2-mutant cells, we found that B-Cell Receptor (BCR) signaling was enhanced after EZH2 
inhibitor treatment, and associated with an activated B-cell phenotype. Genetic manipulation 
of BCR, CD19 and CD79A greatly increased sensitivity to the EZH2 inhibitor EPZ-6438. 
Combination therapy with SYK, PI3K and BTK kinase inhibitors was highly synergistic in 
multiple lymphoma cell lines, regardless of EZH2 mutation status. At the epigenetic level, 
prolonged treatment with EPZ-6438 increased global levels of Histone H4 Arginine-3 
asymmetric di-methylation. In a subset of lymphoma cell lines, combination therapy with EZH2 
and Type I PRMT inhibitors showed synergy. Interestingly, Type I PRMT inhibitors were also 
highly effective as a single-agent, and mediated apoptosis in lymphoma cells by 
transcriptionally down-regulating the anti-apoptotic protein BCL2. To summarize, we have 
identified ways to improve EZH2 inhibitor sensitivity in DLBCL cells and revealed a critical role 
for the arginine methyltransferase PRMT1 in the regulation of lymphoma growth and survival. 
Therefore, PRMT1 presents a novel and promising target for the treatment of this cancer type. 
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1.1 Biology of Germinal Center B-Cells  
1.1.1 T-cell-independent and -dependent humoral immunity 
As part of our body’s adaptive immunity, humoral immune responses stem from antibodies 
generated by B-cells in response to foreign antigens. Humoral immunity can be further 
subdivided into T-cell-dependent and -independent types. Athymic mice cannot form germinal 
centers due to the absence of thymus-derived T-cells. Therefore, Germinal Centers (GC) 
represent a T-cell-Dependent (TD) immune response. Two signals are required for B-cell 
activation after initial encounter with antigen. The first signal is binding of the protein antigen 
to the B-Cell Receptor (BCR), and the second signal is supplied by cognate help from T-cells. 
On the other hand, athymic mice maintain responsivity to nonprotein antigens, representing 
T-cell-Independent (TI) responses. TI Type-1 (TI-1) antigens can elicit responses in CBA/N 
mice, which lack functionality of Bruton’s Tyrosine Kinase (BTK), while TI Type-2 (TI-2) 
antigens are not able to elicit responses in these mice (1). TI-1 antigens, such as gram-
negative bacteria-derived Lipopolysaccharides (LPS) and CpG nucleotides, or virally-derived 
RNA and coat proteins, bind nonspecifically to the BCR and additionally provide a second 
signal through Toll-like Receptor engagement. TI-2 antigens are typically structurally 
repetitive, causing extensive crosslinking of the BCR and leading to strong and sustained 
downstream signaling mediated by BTK. TI-2 antigens are most often derived from bacterial 
capsular polysaccharides and viral capsids. Follicular B-cells are mainly responsible for TD 
responses, whereas TI responses are mediated by Marginal Zone (MZ) B-cells and peripheral 
B-1 cells. B-1 cells offer the earliest and fastest defense against bacterial infection by 
producing large amounts of IgM, the natural immunoglobulin. MZ B-cells swiftly differentiate 
into short-lived plasma cells after encountering TI-1 and TI-2 antigens. Although the traditional 
view has been that TI responses do not generate B-cell memory unlike TD responses, many 
recent studies have challenged such a view. It is now apparent that there are T-cell-dependent 
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but GC-independent ways to generate memory B-cells even in response to TI antigens. Rag1-
deficient mice receiving B-1b cells from T-cell-deficient donor mice infected with B. hermsii 
were able to mount a swift immune response when challenged with the pathogen (2). In some 
cases, TI antigens can lead to the formation of GCs, albeit short-lived and involving very 
limited affinity maturation of GC B-cells. 
1.1.2 The Germinal Center Reaction 
The Germinal Center reaction is a T-cell dependent immune response. In secondary lymphoid 
organs, Dendritic Cells (DCs) in the interfollicular T-cell zone present antigen to naïve CD4+ 
T-cells, which then mature into Pre-Follicular Helper T-cells (Pre-Tfh). The GC reaction is 
initiated when pre-Tfh cells present antigen to naïve B-cells (3). B-cells enter the dark zone, 
where they undergo clonal expansion and mutate their antibody genes through the process 
of Somatic Hypermutation (SHM) (4). In this step, EZH2 is critical to maintain proliferation and 
suppress DNA damage checkpoints which may become activated during hypermutation (5). 
SHM is largely restricted to the antibody genes, but can sometimes spill over to other genes. 
Once the cells complete SHM, they move to the light zone, and EZH2 levels decrease. B-cells 
that have generated antibodies with improved affinity can bind to Follicular Dendritic Cells 
(FDC) coated with antigen (Figure 1). In turn, these B-cells receive positive selection signals 
from FDCs and Tfh cells (6). These signals are delivered through TNF-superfamily ligands like 
CD40L, BAFF and APRIL. Binding of these ligands to cognate receptors on the B-cells 
activate pathways that mediate cell survival, mainly the canonical and non-canonical NFB 
pathways. In addition to cell survival, downstream effects of the NFB pathway include 
activation of target genes that promote differentiation into different lineages: short-lived and 
long-lived plasma B-cells, and memory B-cells (7). Some of these cells may re-enter the dark 
zone to undergo more SHM and acquire antibodies with higher affinity for the antigen. The 
end result of the germinal center reaction is the generation of effector (plasma) B-cells that 
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secrete antibodies to clear the infection, and also the production of memory B-cells which 
remain dormant to fight future infections. Class-Switch Recombination (CSR) occurs in the 
light zone upon binding of the BCR to antigen. Coupled with CD40 engagement, this leads to 














Figure 1. The Germinal Center Reaction. Exposure of naïve B-cells to foreign antigen leads 
to the formation of germinal centers in secondary lymphoid organs. Germinal Center B-cells 
proliferate extensively in the dark zone and undergo Somatic Hypermutation (SHM) to mutate 
their antibody genes. Upon exit to the Light zone, B-cells which have acquired higher affinity 
for the antigen receive survival signals from Follicular Dendritic Cells (FDC) and Follicular 
Helper T-cells (TFH). These B-cells may cycle back to the dark zone to undergo further SHM, 
or differentiate into plasmablasts and precursors of memory B-cells. This image is published 





1.1.3 Tonic and antigen-dependent B-Cell Receptor signaling 
In the dark zone, GC B-cells called ‘centroblasts’ undergo somatic hypermutation and mutate 
their antibody genes to acquire higher affinity for the antigen presented to them. At this stage, 
the B-Cell Receptor is not active, but generates a basal low-level signal that promotes cell 
survival. This type of BCR signaling is called ‘tonic signaling’ (9). After SHM, when 
centroblasts exit the dark zone and enter the light zone, they become ‘centrocytes’ with active 
BCR. This is the zone where their specificity for antigen is tested by FDCs. When a BCR can 
bind to the presented antigen with moderate to high affinity, this activates downstream 
signaling pathways promoting cell proliferation and survival. At the highest level, BCR 
signaling is propagated via phosphorylation of the co-receptors CD79A and CD79B (formerly 
named Ig and Ig). CD79A/B are phosphorylated on Immunoreceptor Tyrosine-based 
Activation Motifs (ITAM; consensus sequence YxxI/Lx6-12YxxI/L), by members of the SRC 
family of kinases (10). Phosphorylation of ITAM motifs attract the SYK tyrosine kinase, which 
then becomes activated through phosphorylation by a SRC family kinase, usually LYN. SYK 
phosphorylates an adaptor protein called BLNK, which brings together Bruton’s Tyrosine 
Kinase (BTK) and Phospholipase-C gamma2 (PLC2). Additionally, LYN and SYK 
phosphorylate a positive co-receptor called CD19, which potentiates BCR signaling by 
activating PI3K and increasing PIP2 to PIP3 conversion. PIP3 recruits Pleckstrin Homology-
domain proteins like PKB/AKT and BTK to the inner leaflet of the plasma membrane to 
facilitate their activation (Figure 2). PLC2 converts PIP3 to the secondary messengers IP3 
and DAG, which in turn activate calcium signaling via PKC. The significance of different co-
receptors, adaptor proteins and kinases in the BCR signaling pathway can be deciphered 










Figure 2. Tonic and antigen-dependent BCR signaling pathways engage different 
downstream effectors. Activation of BTK, PLC2, and calcium signaling can only be 
observed with antigen-type signaling. Both tonic and antigen-type signaling activate SYK and 
PI3K/AKT pathways. Tonic signaling can utilize PI3K and PI3K isoforms interchangeably, 






LYN: B-cells in mice with LYN-/- maintain sensitivity to BCR ligation, suggesting that other 
SRC family kinases can compensate for the lack of LYN. In fact, these cells demonstrate 
hyperactivation of many downstream components like AKT and ERK, accompanied by 
enhanced calcium signaling. On the other hand, global tyrosine phosphorylation is delayed 
and reduced following BCR ligation. This phenomenon stems from deficient tyrosine 
phosphorylation of Immunoreceptor Tyrosine-based Inhibition Motifs (ITIM; consensus 
sequence S/I/V/LxYxxI/V/L) on negative co-receptors of the BCR, a phenomenon that is 
attributed to LYN. LYN-mediated feedback phosphorylation of ITIM motifs on CD22 and 
FcRIIB1 are responsible for the recruitment of SHP1 and SHIP1 phosphatases that down-
regulate BCR signaling (12). LYN-/- mice also display enhanced PI3K activity at the basal 
level and after BCR ligation. LYN promotes association of CSK with PAG (Phosphoprotein 
Associated with Glycosphingolipid-enriched microdomains) by phosphorylating multiple CSK-
binding sites (13). CSK negatively regulates the activation of other Src Family Kinases, 
leading to signal attenuation downstream of BCR. In LYN-/- mice, Fyn showed enhanced 
activity as a consequence of impaired CSK recruitment. These mechanisms may explain the 
autoimmune phenotype characteristic of LYN-/- mice.     
PI3K isoforms: The Type I Phosphoinositide 3-Kinases consist of PI3K, PI3K, PI3K, and 
PI3K isoforms. These enzymes are dual lipid and protein kinases that catalyze the 
conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
trisphosphate (PIP3). PI3Ks are heterodimers, consisting of a p100 catalytic subunit and a 
p85 regulatory subunit. PI3K and PI3K are expressed in all organs, whereas PI3K and 
PI3K are usually found in cells of hematopoietic lineage (14). PI3K,  and  are activated 
after Receptor Tyrosine Kinase (RTK) stimulation, through binding to phosphorylated tyrosine 
motifs in the cytoplasmic domain of the receptor or through binding to similar motifs in adaptor 
proteins like GAB2. PI3K is distinct from these other isoforms, and associates with G-Protein 
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Coupled Receptors (GPCR).  PIP3 production by PI3K is critical for BCR signaling. Many 
downstream regulators such as PLC2, BLNK, BTK and Vav, contain Pleckstrin Homology 
(PH) domains which allow them to bind to PIP3 and localize to the plasma membrane.  
PI3K and PI3K are essential for the normal functioning of multiple organ systems. As a 
consequence, knockout of PI3K and PI3K causes embryonic lethality. On the other hand, 
PI3K and PI3K ablation in mice is not associated with any significant effects on development 
and viability (15, 16). In these mice, aberrant phenotypes are manifested only upon challenge 
of the immune system. PI3K deficiency is associated with diminished T-cell activation, and 
faulty recruitment of macrophages and neutrophils in response to inflammatory stimuli. On the 
other hand, PI3K deficiency is associated with extensive defects in B-cell development. 
PI3K-deficient mice display defective BCR signaling, compromised IL-4 mediated survival 
effects, and impaired responses to both TI and TD antigens.  
SYK: Spleen Tyrosine Kinase (SYK) is a cytoplasmic tyrosine kinase which functions as a 
critical mediator of signal propagation downstream of the BCR. In fact, most of the effects of 
BCR ligation are facilitated by SYK.  The tandem SH2 domains of SYK bind to phosphorylated 
ITAMs on CD79A and CD79B after BCR ligation (17). As a consequence, SYK knockout leads 
to perinatal lethality in mice, making it considerably difficult to study in vivo (18). Tyrosines-
526/526 located in the activation loop are auto-phosphorylated by SYK, although LYN may 
initially contribute to this. Phosphorylation of SYK at Y323 negatively regulates its activity and 
recruits Cbl, leading to its ubiquitination and degradation.    
BTK: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic kinase that was identified as the 
product of the gene responsible for causing X-linked Agammaglobulinemia (XLA) in humans 
(19). Patients with this disorder suffer from an impaired humoral immune response caused by 
the lack of antibody-producing plasma cells. BTK consists of PH, Tec homology, SH3, SH2 
and SH1 domains. Interestingly, mutations in BTK represent the highest number of mutations 
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found in a kinase gene. The phenotype associated with Xid (X-linked immunodeficiency) mice 
result from a disruptive R28C mutation in the phospholipid-binding PH domain of BTK, which 
prevents localization of the kinase to the inner leaflet of the plasma membrane. BTK is 
activated by LYN-mediated phosphorylation of Y551, which then promotes 
autophosphorylation at Y223 (19). BTK is inactivated by serine/threonine phosphorylation 
performed by AKT and PKC. AKT-induced phosphorylation recruits 14-3-3 proteins and 
leads to BTK degradation (20).   
1.1.4 Positive and negative co-receptors of the BCR 
CD19: CD19 is a transmembrane protein which functions as a positive co-receptor of the 
BCR. CD19 forms a complex with Complement Receptor-2 (CD21) and Tetraspan Membrane 
Protein TAPA-1 (CD81). This complex functions to lower the threshold for BCR activation in 
response to initial antigen binding (21). The CD19 cytoplasmic tail has nine conserved tyrosine 
residues. The tyrosine residues at positions 482 and 513 lie within YXXM SH2-binding motifs, 
which recruit the p85 subunit of PI3-Kinase. Therefore, tyrosine phosphorylation of CD19 is 
primarily responsible for PI3K activation. Accordingly, studies have showed that PTEN 
deletion in CD19-/- mice can rescue GC B-cell formation by allowing sustained PIP3 
generation. CD19-mediated activation of LYN induces feedback inhibition of BCR signaling 
via increased phosphatase activity (SHP1). B-cells in CD19-deficient mice do not respond to 
TD (KLH), TI-1 (LPS), and TI-2 antigens, except for Ficoll towards which they demonstrate 
hyperresponsivity. CD19-/- mice show reduced serum Ig levels, and the isotypes IgG1 and 
IgG2a are the most affected (22). CD19 is required for initial B-cell activation in response to 
TD antigen, and generation of memory B-cells at a later stage in the germinal center.  
CD22: Negative co-receptors play a key role in the down-regulation of BCR signaling. CD22 
is an inhibitory co-receptor of the BCR that belongs to the Siglec family. It is a transmembrane 
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protein that consists of an extracellular domain that binds sialylated glycans, and a 
cytoplasmic domain that is involved in signaling (23). Binding to sialylated glycans allows 
discrimination between self and non-self, and promotes B-cell tolerance. Interestingly, CD22 
is a strong cis-ligand for itself, and forms homooligomers. Binding to cis ligands reduces its 
availability for binding to the BCR. Disruption of CD22 homooligomers promotes its 
association with the BCR, and potently controls antigen-induced signaling. CD22 contains 
ITIMs in its cytoplasmic domain, which functions to recruit and activate phosphatases, thereby 
dampening BCR signaling. BCR ligation leads to rapid phosphorylation of CD22 on ITIMs by 
LYN kinase, and recruits SHP-1 phosphatase (12). SHP-1 then dephosphorylates the adaptor 
protein BLNK/SLP65 which bridges PLC2 to BTK, and promotes attenuation of calcium 
signaling.  
CD72 and its ligand CD100/Sema4D: Similar to CD22, CD72 also functions as an inhibitory 
co-receptor that down-regulates BCR signaling. CD72 is a transmembrane protein belonging 
to the C-type lectin family, which also contains ITIMs in its cytoplasmic domain. CD72 is a 
low-affinity receptor for the semaphorin ligand CD100 (Sema4D), which also serves as a 
ligand for Plexin-B1 and regulates axon guidance in the central nervous system (24). In the 
absence of ligand stimulation, CD72 remains unphosphorylated and facilitates constitutive 
SHP1 phosphatase activity. However, upon binding to CD100, it becomes phosphorylated 
and SHP1 activity is switched off (25). This facilitates enhanced BCR signaling (Figure 3). 
CD100 is expressed by multiple cell types in the immune system, and also amplifies the effect 










Figure 3. CD100/Sema4D is a ligand for the negative co-receptor CD72. (a) Homotypic 
interactions between activated B-cells expressing CD100/Sema4D enhances BCR signaling 
by engaging the negative co-receptor CD72 and ‘switching off’ its inhibitory function. (b) In a 
similar fashion, CD100/Sema4D expressed by CD4+ T-cells aid in B-cell activation and 
maturation by amplifying CD40 signaling. This image is published with permission from Nature 






1.2 Diffuse Large B-Cell Lymphoma 
1.2.1 Subtypes of Diffuse Large B-Cell Lymphoma 
Diffuse Large B-Cell Lymphoma can be classified into different subtypes based on the gene 
expression profile and immunohistochemistry: Germinal Center B-cell-like (GCB), Activated 
B-cell-like (ABC) and Primary Mediastinal B-cell Lymphoma (PMBL) (28). The GCB subtype 
of DLBCL expresses BCL6 and CD10, which is characteristic of centroblasts in the dark zone 
of the germinal center. This subtype is also predictive of better overall survival rates and 
favorable response to the standard-of-care chemoimmunotherapy. In comparison, the ABC-
subtype of lymphoma is associated with poor prognosis (29). ABC-DLBCL expresses 
differentiation markers like IRF4/MUM1, which resemble centrocytes in the light zone of the 
germinal center (30). Over the last decade, new algorithms for more accurate 
immunohistochemical classification of DLBCL subtypes have been developed, and these 
methods continue to evolve over time (31, 32). Sequencing of DLBCL patient samples have 
revealed mutations in genes that play an important role in the normal germinal center (33). 
Some of these mutations target components of BCR and NFB signaling (CD79A/B, CARD11, 
MYD88), epigenetic regulators involved in B-cell development (MLL2/3, CREBBP, EP300, 
EZH2), critical transcription factors and apoptosis regulators (MYC, TP53, BCL2, PRDM1). 
1.2.2 Epigenetic deregulation in DLBCL 
Combinations of posttranslational modifications on histone tails may govern transcriptional 
activation or repression at specific genes (34). These modifications include lysine and arginine 
methylation, lysine acetylation, and lysine ubiquitination, to name a few. When these marks 
are present at specific locations on a histone tail, they may signal either transcriptional 
activation or repression. For example, lysine acetylation affects the charge on a histone tail 
by reducing the positive charge on the lysine residue (35). This weakens interactions between 
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the negatively-charged DNA and the histone tail, and ‘opens up the chromatin’ to facilitate 
recruitment of transcription factors. On the other hand, modifications like lysine/arginine 
methylation do not have an impact on charge, but mediate their effects by creating binding 
sites for proteins called ‘readers’ (36, 37).  These proteins can recognize specific modifications 
and assemble protein complexes to effect changes to the transcriptional status of a gene. 
Histone methyltransferases and acetyltransferases are examples of ‘writers’ that catalyze 
these various histone modifications (38). EZH2 is a histone methyltransferase that catalyzes 
Histone H3 Lysine-27 tri-methylation (H3K27me3) at enhancer and promoter regions (Figure 
4a). This particular modification promotes transcriptional repression and ‘switches off’ gene 
expression. KMT2C/MLL3 and KMT2D/MLL2 are histone methyltransferases that catalyze 
Histone H3 Lysine-4 methylation (39). H3K4me1 is a modification that is enriched at enhancer 
regions, while H3K4me3 is typically found at promoter regions. EP300 and CREBBP are 
histone acetyltransferases that catalyze lysine acetylation on a variety of different histone tail 
residues. Interestingly, mutations in epigenetic ‘writers’ are rampant in different cancer types, 
including DLBCL. 
EZH2 mutations are exclusively found in GCB-DLBCL tumors, whereas KMT2C/2D, EP300 
and CREBBP mutations are found in both ABC and GCB subtypes (40). The most common 
alterations in EZH2 that occur in DLBCL are gain-of-function mutations that lead to enhanced 
H3K27me3 deposition at differentiation-associated genes. Loss-of-function mutations in 
KMT2D/2C, CREBBP and EP300 compromise their catalytic activities to block activation of 
differentiation-associated genes (41-44). Therefore, mutations in these epigenetic ‘writers’ co-
occur in many DLBCL tumors, and act together to maintain B-cells in a stem-like state (Figure 
4b) (45-47). Overall, epigenetic mutations in DLBCL shift the balance towards global gene 
repression (Figure 4c). However, this also creates many opportunities for therapeutic 
intervention. CREBBP and EP300 are commonly associated with acetylation at enhancer 
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regions, which is followed by recruitment of bromodomain-containing proteins. As a 
representative example, the Bromodomain and Extra-Terminal (BET) family of proteins are 
‘readers’ of lysine acetylation that were first identified due to their heavy asymmetric loading 
at enhancer regions (48). In DLBCL, BRD4 is recruited to the super-enhancers of critical 
transcription factors such as POU2AF1, PAX5, IRF8 and BCL6, to name a few (49). BET 
bromodomain inhibitors like JQ1 and OTX015 demonstrate therapeutic efficacy against a wide 
range of different tumor types, including hematologic malignancies. Bromodomain inhibitors 
are effective against lymphoma, and lead to cell cycle arrest, senescence or apoptosis in 




























Figure 4. Epigenetic regulators are frequently mutated in diffuse large B-cell 
lymphoma. (a) The methyltransferases KMT2D/2C (also known as MLL2/3) catalyze 
H3K4me1 at enhancer regions and H3K4me3 at promoter regions. Enhancers containing both 
H3K4me1 and EZH2-catalyzed H3K27me3 maintain a ‘poised’ state. De-methylation of 
H3K27me3 by KDM6A (UTX) leads to enhancer activation, facilitates histone acetylation by 
EP300/CREBBP (p300/CBP) and promotes gene expression. (b) Without subtype 
classification, loss-of-function mutations in KMT2D (21%) and CREBBP (25%) are the most 
frequent, while EZH2 gain-of-function mutations occur in 10% of all DLBCL cases (cBioPortal). 
Mutations in different epigenetic enzymes co-occur in lymphoma patients (45-47). 25-30% of 
patients with the GCB subtype of DLBCL harbor EZH2 mutations. (c) In lymphoma, mutations 
targeting epigenetic enzymes ‘switch off’ transcriptional activators (KMT2D/CREBBP) and 
hyperactivate the transcriptional repressor EZH2, shifting the balance towards global gene 







1.2.3 Consequences of EZH2 mutation in GCB-DLBCL 
In 2010, studies first reported the identification of EZH2 mutations in 25-30% of GCB-DLBCL 
cases (53). These mutations are localized to the catalytic SET domain of EZH2, and the three 
most commonly mutated sites are Y641, A677 and A687 (54-56).  Due to their location, they 
were first believed to be loss-of-function mutations, but research later showed that these 
mutations conferred gain-of-function activity to EZH2. EZH2 is the catalytic core component 
of the Polycomb Repressive Complex 2 (PRC2), which methylates Histone H3 Lysine-27. 
EZH2 is capable of mono-, di- and tri-methylating H3K27, with tri-methylation generating a 
repressive modification that switches off gene expression, usually through recruitment of the 
Polycomb Repressive Complex 1 (PRC1) complex which performs Histone H2A Lysine-119 
mono-ubiquitination (H2AK119ub) (57). While wildtype EZH2 is highly capable of catalyzing 
mono- and di-methylation of H3K27, mutations in the substrate-binding channel render the 
mutant EZH2 enzyme superior at catalyzing the di- to tri-methylation reaction. Together, the 
combination of wildtype and mutant EZH2 produce high global levels of H3K27me3, leading 
to widespread gene repression (58, 59). Accordingly, EZH2 mutations are found to be 
heterozygous in DLBCLs, with a wildtype allele necessary to maintain optimal H3K27me3 
levels. Recent studies have showed that the EZH2 mutants A677G and A687V can catalyze 
all three steps of H3K27 methylation on their own, without the need for wildtype EZH2 (Figure 
5a). For this reason, they have been dubbed ‘super-mutants’. Similarly, Y641F displays a 
limited capacity to catalyze all three methylation reactions, while all other Y641X (X=N/S/H/C) 
mutations cannot do this (Figure 5b). In the presence of wildtype EZH2, the Y641N/S mutants 
are comparable to A677G, A687V, and Y641F, but superior to Y641H/C at catalyzing 
H3K27me3.  
Therefore, it is apparent that all EZH2 gain-of-function mutations are not identical, and each 
one may influence the level of dependency of lymphoma cells on EZH2 activity (Figure 5c). 
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For example, the cell line Pfeiffer harbors an A677G mutation, and displays remarkable 
hypersensitivity to EZH2 inhibitors, exceeding the response of all other EZH2-mutant cell 
lines. SUDHL-10 and WSU-DLCL2, which both harbor Y641F mutations, exhibit significant 
cytotoxic responses to the EZH2 inhibitor GSK126 (60). On the other hand, Y641X mutations 
in EZH2 are present in many lymphoma cell lines, but display a broad spectrum of sensitivity 
to EZH2 inhibitors. Cell lines RL and SUDHL-4 harbor Y641N and Y641S mutations 
respectively, but are resistant to EZH2 inhibition, while SUDHL-6 and DB both harbor Y641N 



















Figure 5. EZH2 mutations and differential sensitivity to EZH2 inhibitor treatment. (a) 
The EZH2 mutants A677G, A687V and Y641F can perform all three (-mono, -di, and –tri) 
methylation reactions at H3K27, without the requirement for wildtype-EZH2. (b) EZH2-Y641X 
(where X=N/S/H/C) cooperates with wildtype EZH2 to generate high levels of H3K27me3. 
Wildtype EZH2 catalyzes H3K27me0 to me1 with high efficiency, while EZH2-Y641X cannot 
perform this reaction. Both wildtype and EZH2-Y641X can transform H3K27me1 to me2 with 
reasonable efficiency. However, only EZH2-Y641X can generate high levels of H3K27me3 
from me2. (c) Table of lymphoma cell lines along with information about EZH2 mutation status 
and sensitivity to the EZH2 inhibitor EPZ-6438 at 11 days of treatment. Within each category 





1.2.4 EZH2 inhibitors and ongoing clinical trials 
EZH2 inhibitors have been developed by multiple pharmaceutical companies, including 
Epizyme, GlaxoSmithKline, and Constellation. All of these inhibitors function by competing 
with the co-factor S-adenosylmethionine for binding to the EZH2 enzyme, and are therefore 
termed SAM-competitive inhibitors. EPZ005687 was the first selective EZH2 inhibitor reported 
to show high efficacy in lymphoma cell lines with EZH2 mutations (61). This was followed by 
GSK126, UNC1999, EPZ-6438, CPI-1205, and ZLD10A (62-65).  Currently, GSK126, EPZ-
6438 and CPI-1205 are in different phases of clinical trial. Phase I clinical trials of EPZ-6438 
in patients with relapsed and refractory DLBCL reported an impressive Objective Response 
Rate (ORR) of 60%. Interestingly, responses were recorded in both EZH2-wildtype and EZH2-
mutant patients. Gene expression profiling of lymphoma cell lines after EZH2 inhibitor 
treatment did not reveal any significant overlap or distinct differences between genes de-
repressed in sensitive and resistant cell lines (60, 63). Therefore, factors that determine 
favorable response to EZH2 inhibitors remain largely unknown. Notably, early results of Phase 
II EPZ-6438 clinical trials reported that the ORR was lower, and a majority of EZH2-wildtype 
patients did not respond to treatment. EZH2-mutant patients showed a 40% ORR, but all were 
partial responses and there were no complete responses. On the other hand, EZH2-wildtype 
patients showed a 14% ORR and exhibited a mix of partial and complete responses.   
1.2.5 Targeted therapies for DLBCL subtypes 
The GCB subtype of DLBCL responds favorably to the standard-of-care R-CHOP therapy 
(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) with an overall survival 
rate of 80% at 5 years post-treatment (29). Rituximab is an anti-CD20 antibody that mediates 
B-cell targeting by Natural Killer (NK) cells through antibody-dependent complement 
cytotoxicity (ADCC) (66). However, patients who relapse or suffer from refractory disease 
have few options. ABC-DLBCL is marked by activating mutations in BCR signaling elements 
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such as CD79A, MYD88 and CARD11. Chronic activation of the BCR signaling pathway is 
responsible for rapid proliferation and survival in the ABC-subtype of lymphoma (67). 
Therefore, targeting kinases in this pathway is a successful strategy for treatment. The BTK 
inhibitor ibrutinib has been largely successful in clinical trials, and represents a breakthrough 
therapy for patients with this subtype of lymphoma (68). Other treatment options for patients 
with ABC-DLBCL are SYK inhibitors (R406, PRT062607), PI3Kinhibitors (idelalisib), PKC 
inhibitors (enzastaurin), NFB pathway inhibitors (bortezomib and lenalidomide), and BCL2 
antagonists (venetoclax) (68-74). On the other hand, GCB-DLBCL is characterized by a basal 
level of antigen-independent BCR signaling, called tonic BCR signaling. In this type of 
signaling, the downstream effects of BCR activation are propagated through SYK and 
PI3K/AKT (9, 10). Interestingly, PTEN deletions have been identified in a significant 
percentage of GCB-DLBCL cases, and lead to increased AKT activation (75). SYK inhibitors 
offer a promising avenue for the treatment of GCB-DLBCL by blocking tonic BCR signaling. 
However, SYK inhibitors would not work in cases where PTEN is deleted. In these instances, 
direct targeting of PI3Kisoforms or AKT would be more effective.  
SYK inhibitors: The first reported orally bioavailable SYK inhibitor is Fostamatinib (R406), 
which shows significant off-target effects on other kinases such as FLT3, JAK1, JAK3 and 
LCK (76). Newer and more specific SYK inhibitors such as PRT062607 (Portola) and TAK-
659 (Takeda) show promise in early stage clinical trials for Chronic Lymphocytic Leukemia 
(CLL), and appear to work well against DLBCL in preclinical experiments (77-80).  
PI3K inhibitors: Idelalisib (CAL101, Gilead) is a potent and specific PI3K inhibitor, which 
does not significantly affect PI3K and PI3Kisoforms. Idelalisib is approved for the treatment 
of CLL, indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) and relapsed Small Lymphocytic 
Lymphoma (SLL). Duvelisib (IPI-145, Infinity) is a dual PI3K/ inhibitor, which has 
demonstrated activity against CLL and T-cell lymphomas. Copanlisib (BAY 80-6946, Bayer) 
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is a dual inhibitor of PI3K/ that showed clinical activity in Mantle Cell Lymphoma (MCL) 
patients (81). One of the major drawbacks of PI3K inhibitors like idelalisib is the adverse 
toxicity observed in patients, especially when combined with other therapies (72).   
BTK inhibitors: Ibrutinib (PCI-32765, Pharmacyclics) is a BTK inhibitor which also targets 
EGFR, ITK, TEC and SRC family kinases at higher doses. Ibrutinib is FDA-approved for the 
treatment of CLL, MCL, Marginal Zone Lymphoma (MZL) and Waldenstrom’s 
Macroglobulinemia (WM) (82). Acalabrutinib (ACP-196) is a novel second-generation BTK 
inhibitor from Acerta Pharmaceuticals, which is more specific for BTK and expected to have 
less off-target toxicity. In clinical trials, acalabrutinib showed efficacy in CLL and lymphomas 
that are difficult to treat (83-86). 
BCL2 antagonists: Another promising class of inhibitors for the treatment of GCB and ABC-
DLBCL are BCL2 antagonists such as Venetoclax (ABT-199, AbbVie) (87). In the germinal 
center, GC B-cells in the dark zone are ‘primed’ for apoptosis and maintain very low levels of 
the anti-apoptotic protein BCL2. As a result, B-cells that acquire deleterious mutations during 
the SHM process will undergo apoptosis. Upon exit into the light zone, survival signals are 
delivered through BCR signaling, CD40L/CD40 engagement and BAFF/BAFF-R ligation (88). 
These signals increase the expression of MCL-1, which is critical for germinal center initiation 
and maintenance (89, 90). In DLBCL and FL, chromosomal translocations drive BCL2 
overexpression and promote resistance to apoptosis. EZH2 mutations commonly co-occur 
with BCL2 chromosomal translocations, and an EZH2-mutant mouse model demonstrates 
lymphomagenesis when combined with BCL2 overexpression (91, 92). Therefore, combining 





1.3 Protein Arginine Methyltransferases in Cancer 
1.3.1 Type I PRMTs and their substrates  
Protein Arginine Methyltransferases are divided into two families, with Type I representing the 
largest family. Type I PRMTs are asymmetric arginine methyltransferases, consisting of 
PRMT1, 2, 3, 4, 6 and 8 (Figure 6a). PRMT5 and PRMT9 are symmetric arginine 
methyltransferases categorized as Type II, and PRMT7 is a mono-methyltransferase 
categorized as Type III. PRMT1 is the major arginine methyltransferase in the cell, contributing 
to 85% of the global arginine methylation (93, 94). PRMT1 is overexpressed in multiple cancer 
types, including breast, prostate, colon, ovarian and pancreatic cancers. PRMT1 and 
PRMT4/CARM1 are best known for their roles as transcriptional coactivators for nuclear 
receptors such as ER(95). PRMT1-mediated asymmetric di-methylation of histone H4 at 
arginine-3 (H4R3me2a) sets off a sequence of events that culminates in transcriptional 
activation (96). One of the earliest studies on PRMT1 function showed that ordered activity of 
PRMT1, p300, and CARM1, was responsible for transcriptional activation by the p53 tumor 
suppressor (Figure 6b) (97). Other studies have also demonstrated that PRMT1 and CARM1 
synergize to activate genes under different contexts (98).  CARM1 methylates histone H3 at 
both arginine-17 and -26, although the former is its major substrate (99).  Arginine methylation 
of histone H3 by CARM1 leads to the displacement of transcriptional repressors from 
chromatin (100). PRMT6 acts as a transcriptional repressor, and catalyzes histone H3R2 
methylation, which blocks H3K4 methylation by MLL proteins (Figure 6c) (101). In addition to 
their activity towards histone substrates, PRMT1 and CARM1 display methyltransferase 
activity towards a variety of non-histone substrates. In breast cancer, CARM1 methylates the 
SWI/SNF chromatin remodeler BAF155 and this methylation promotes tumor cell migration 
and metastasis (102). Arginine methylation of the RNA polymerase II subunit MED12 by 
CARM1 improves sensitivity to chemotherapy drugs (103). Although CARM1 mainly functions 
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as a transcriptional coactivator, there are instances where it also promotes repression. 
Methylation of RUNX1 by CARM1 leads to the assembly of a multi-protein repressor complex 
that blocks myeloid differentiation of Hematopoietic Progenitor/Stem Cells (HPSCs) (104). 
Another example is CARM1-mediated methylation of the acetyltransferase CREBBP, which 
negatively modulates its transcriptional coactivator function by blocking its interaction with 
CREB (105). Therefore, in these contexts, CARM1 acts directly or indirectly to promote 
transcriptional repression. Similarly, there are a few cases where PRMT1 promotes 
repression of genes, such as HIF1 and HIF2 (106). PRMT1 is implicated in pro-oncogenic 
functions across many cancer types. In colon cancer, PRMT1 methylates EGFR and promotes 
resistance to the monoclonal antibody cetuximab (107). In pancreatic cancer, PRMT1 
methylates GLI1 and increases activation of its target genes (108). In breast cancer, PRMT1 
activates ZEB1 at the transcriptional level, and promotes the Epithelial-to-Mesenchymal 
Transition (EMT) (109). In glioblastoma, PRMT1 links 5-hydroxymethylcytosine to gene 
activation via H4R3 methylation activity (110). In acute myelogenous leukemia, PRMT1 
supports the oncogenic function of MLL-fusion proteins in partnership with the histone H3K9 
demethylase KDM4C (111). The importance of PRMT1 in the cell is exemplified by extensive 
substrate scavenging performed by other PRMTs when PRMT1 is knocked out in mouse 
embryonic fibroblasts (112). This shows that Asymmetric Dimethyl Arginine (ADMA) formation 
by PRMT1 serves as a placeholder to prevent accumulation of Monomethyl Arginine (MMA) 








Figure 6. Type I PRMTs methylate histone tails on arginine residues to regulate gene 
expression. (a) Type I PRMTs can perform mono-methylation or asymmetric di-methylation 
at arginine residues.  (b) PRMT1 and PRMT4/CARM1 catalyze asymmetric di-methylation at 
histone H4 arginine-3 (H4R3me2a) and histone H3 arginine-17 (H3R17me2a) respectively to 
activate gene expression. During this process, histone acetyltransferases such as p300/CBP 
may cooperate with PRMT1 and CARM1. (c) PRMT6 catalyzes asymmetric di-methylation of 
Histone H3 at Arginine-2 (H3R2me2a) to block Lysine-4 tri-methylation (H3K4me3) and gene 
activation by the MLL protein complex.   
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1.3.2 Structural attributes of PRMT1 and CARM1 
PRMT1 and CARM1 possess a Rossman fold that is typical of methyltransferases from this 
family (113). The catalytic core of PRMTs consist of the cofactor-binding Rossman fold and a 
-barrel. Many type I PRMTs, including PRMT1 and CARM1, are known to undergo homo-
dimerization. The dimerization arm emerging from the -barrel of one PRMT monomer makes 
contacts with the Rossman fold of the other PRMT monomer, with both of them arranged in 
head-to-tail orientation. The N-terminal section preceding the Rossman fold consists of 
multiple -helices, which are involved in formation of the cofactor binding site and the 
dimerization interface (114). The structure of PRMT1 exemplifies the typical structural 
characteristics of Type I PRMTs. On the other hand, CARM1 possesses a unique N-terminal 
domain which adopts a PH-like superfold conformation (115). Historically, PH-domains have 
been associated with binding to phospholipids, such as BTK binding to PIP3. However, PH-
domains are extremely diverse, and in fact only a minority of them bind to phospholipids. This 
domain regulates protein-protein interactions by binding to proline-rich regions, 
phosphorylated or unphosphorylated tyrosine residues (116). The latter two types of 
interactions are characteristic of Phosphotyrosine Binding Domains (PTBs) present in Insulin 
Receptor Substrate 1 (IRS1). In the case of CARM1, the N-terminal domain forms a 
homodimer with another CARM1 molecule, which would prevent its involvement in binding to 
other proteins. However, in instances where the dimer dissociates, the PH-like domain could 
play a role in promoting interactions with other proteins. In fact, it was reported very recently 
that the N-terminal domain of CARM1 plays a critical role in the recognition and methylation 
of its substrates (117). The central portion of CARM1 possesses methyltransferase activity, 
and the C-terminal domain is involved in its transactivation function. Interestingly, the C-
terminal domain also contains an auto-methylation site (R551) that is reported to be 
extensively di-methylated in vivo (118). Mutation of this auto-methylation site does not affect 
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CARM1’s catalytic activity, but abrogates its ability to activate transcription and pre-mRNA 
splicing. 
1.3.3 Therapeutic potential of PRMT inhibitors in cancer treatment 
In the last few years, small-molecule inhibitors targeting PRMTs have been developed. 
Although PRMT5 inhibitors are far ahead in pre-clinical development, there have been few 
selective inhibitors of the Type I PRMTs. The aryl pyrazole derivative compound EPZ020411 
(Epizyme) is the first reported PRMT6 inhibitor, which also demonstrates off-target effects on 
PRMT1 and PRMT8 at higher concentrations (119). Based on the structure of EPZ020411, 
the Structural Genomics Consortium developed MS023, a pan-Type I PRMT inhibitor which 
affects PRMT1, 3, 4, 6, and 8 (120). MS049 inhibits PRMT4 and PRMT6, but does not affect 
PRMT1 activity (121). SGC707 is an allosteric inhibitor of PRMT3, which makes it highly 
specific (122). Structural similarities make it difficult to obtain inhibitors with high selectivity 
towards PRMT1 over the other type I PRMTs. AMI-1 was the first reported small-molecule 
inhibitor of PRMTs that demonstrated specificity towards arginine methyltransferases, unlike 
other published inhibitors that also targeted lysine methyltransferases (123). In recent times, 
an early phase PRMT1 inhibitor called AMI-408, which was derived from AMI-1, has been 
used successfully for in vivo studies in acute myeloid leukemia (111). Many new compounds 
are in preclinical development by pharmaceutical companies. Over the next few years, we 
can expect highly selective and specific inhibitors against PRMT1, CARM1, and PRMT6 to be 




























2.1 Cell Culture 
Diffuse Large B-Cell Lymphoma cell lines SUDHL-6, SUDHL-4, RL, HT, DB, U-2932, SUDHL-
5, SUDHL-7, HBL-1, SUDHL-10, Toledo and Pfeiffer were maintained in RPMI-1640 medium 
containing 10% heat-inactivated Fetal Bovine Serum and 1% Penicillin-Streptomycin. 
Knockout and mutant versions of SUDHL-6, DB, SUDHL-10, SUDHL-7, OCI-Ly7 and OCI-
Ly8 were maintained in the same medium. All DLBCL cell lines were obtained from Dr. R.E. 
Davis. 293T and MCF7 cells were cultured in DMEM/F12 medium supplemented with 10% 
FBS, penicillin, streptomycin and glutamine. 
2.2 Cell Growth Assays 
Cell growth was measured using the CellTiter-Glo Viability Assay from Promega. Cells were 
seeded at a density of 20,000 cells/ml in 384-well plates and incubated with serial dilutions of 
inhibitors. After 4 days of treatment, the cells were split and fresh media containing inhibitor 
was added. At 8 days, the assay was completed by adding CTG assay buffer equal to the 
volume of media in each well, and luminescence was determined using a Synergy H4 Hybrid 
Reader.   
2.3 Apoptosis Assays 
After drug treatment, apoptosis was measured via flow cytometry. Live cells were incubated 
with CaspGLOW Active Caspase reagent (Biovision) for 1 hour, and FITC+ cells were 
quantified using a BD FACS Aria flow cytometer. Alternatively, cells were stained with 7-
Aminoactinomycin-D and Annexin V (Biolegend). Single-stained and double-stained cells 
were examined to identify early apoptotic, late apoptotic and necrotic cells. FlowJo software 




2.4 Cell Cycle Analysis 
Cells were fixed with cold 70% ethanol for 2 hours and treated with RNase to eliminate RNA 
contamination. Propidium iodide (Biolegend) was added to stain the DNA, and cells were 
analyzed using a BD FACS Aria flow cytometer. Cell cycle staging was performed using 
FlowJo software.   
2.5 Determination of IC50 and drug synergy  
Data from CellTiter-Glo assays was graphed using GraphPad Prism software, and non-linear 
regression analysis was utilized to generate IC50 values. For drug synergy experiments, 
CompuSyn software Version 1.0 (ComboSyn) was used to compute Combination Index 
values using the Chou-Talalay method. 
2.6 Generation of BCR-KO, CD19-KO, and CD79A-mutant cell lines 
All knockout cell lines and CD79A-mutants were generated using the CRISPR/Cas9 system, 
by O Havranek and RE Davis. Chimeric plasmids from the Zhang laboratory were used for 
this technique: pX330-U6-Chimeric_BB-CBh-hSpCas9 (pX330; Addgene plasmid # 42230, 
coding for Cas9 as well as gRNA) and pSpCas9(BB)-2A-GFP  (pX458; Addgene plasmid # 
48138; coding for Cas9 linked by 2A peptide with GFP and for gRNA expression) (124, 125). 
The online CRISPR Design Tool from the Zhang laboratory was used to design target 
sequences (http://crispr.mit.edu/) (126). Target sequences were ligated as annealed oligos 
into BbsI-opened pX330, pX335, or pX458 plasmids according to the published protocol. After 
verification of gRNA sequences, transfections were performed with electroporation to deliver 
maxiprep DNA. For each electroporation, 12 µg of plasmid DNA was delivered (pX330 or 
pX458, with cloned gRNA sequence) per 120 µL of cell suspension (1 million cells per 100 
µL) in electroporation buffer. Cells with successful knockout were detected by flow cytometry 




CD79A mutations were introduced in the last two exons (exon 4 and 5), which code for the 
ITAM domain. Double-strand breaks in both exons were generated using two pX330 plasmids 
as outlined in the table below. Homology arms upstream of the CRISPR/Cas9 target site in 
exon 4 and downstream of the target site in exon 5 were included in the Homologous 
Recombination template. This allowed efficient translation of the endogenous CD79A exon 4 
while exon 5 was translated from the knocked-in sequence, which ended with a stop codon 
and a bGH polyA signal sequence. Using this method, three different versions of CD79A were 
generated: wildtype full-length CD79A with GFP fusion, full-length CD79A-GFP fusion with a 
Tyrosine to Phenylalanine mutation (Y188F), and full-length CD79A-GFP fusion with an 
Arginine to Lysine mutation (R204K). Both the pX330 plasmids (6 µg each) and the HR 
template plasmid (7 µg) were delivered through electroporation to 1.2 million cells re-
suspended in 120 µL of R or T buffer.  
 







BCR KO in 
SUDHL-6 
IGHG-C4 CGGTGAGGACGCTGACCACACGG pX330 




exon 6 of 
IGHG3 




IGHM-C4 AGATGAGCTTGGACTTGCGGGGG pX330 
exon 2 of 
IGHM 
BCR KO in 
Ly8  
CD19_01 TGGAATGTTTCGGACCTAGGTGG pX330 
exon 3 of 
CD19 
CD19 KO 
Name Target Sequence (5’ to 3’) Plasmid Location Use 
CD79A modifications 
















2.7 PRMT1 siRNA transfection 
Knockdown was achieved using PRMT1-specific siRNA (SASI_Hs01_00133430, 
SASI_Hs01_00133431 and SASI_Hs01_00133433) or universal negative control siRNA 
(Sigma) and an Amaxa Nucleofector II (Lonza). Electroporation was performed using program 
number O-017, according to the manufacturer’s protocol. 
2.8 Real-time Quantitative PCR 
Total RNA was isolated from cell lines using the RNeasy Mini Kit (Qiagen). Reverse 
transcription was performed using Superscript III First-strand Synthesis System (Fisher). 
Real-time PCR was completed with iQ SYBR Green Supermix (Biorad) and a plate reader. 
BCL2_F1: 5’-TGCACCTGACGCCCTTCAC-3’ 
BCL2_R1: 5’-CTCTCCACACACATGACCCC-3’ 
ACTB_F1: 5’-AGAGCTACGAGCTGCCTGAC-3’              





P_BCL2_F4 (ChIP): 5’-CCCTTGTTTTCATGGCGCAC-3’ 





2.9 Chromatin Immunoprecipitation 
ChIP assay was performed using the Millipore Magna ChIP A/G Kit. Sonication was done 
using a sonicator bath and 3 cycles of 10 pulses each was used to shear the chromatin. 10ug 
of H4R3me2a antibody or an equal amount of Rabbit IgG antibody was added. The control 
primer mix for GAPDH was obtained from the kit. 
2.10 Protein Immunoprecipitation 
Cell lysates were prepared in RIPA buffer. Anti-FLAG M2 affinity beads (Sigma A2220) were 
incubated with lysate for 4 hours at 4ºC. Beads were washed four times for fifteen minutes 
each and 3X-Flag peptide was used as elution buffer. After incubation for thirty minutes at 
room temperature, the eluate was collected and boiled at 95ºC with SDS-PAGE loading buffer 
added.   
2.11 Imaging  
SUDHL-6 and DB cells expressing CD79A-GFP were imaged over the course of 7 days of 
EPZ-6438 treatment using an Incucyte Zoom instrument at 20X magnification. For Duolink 
Proximity Ligation Assay, MCF7 cells were imaged using a Leica confocal microscope.  
2.12 Mass Spectrometry 
MCF7 breast cancer cells expressing myc-tagged EZH2 were cultured in 150mm dishes, 
collected and frozen as cell pellets. Pellets were thawed and lysed with RIPA buffer. Anti-c-
Myc affinity beads were incubated with lysate overnight and washes were performed. Bound 
protein was eluted and concentrated using Trichloroacetic acid precipitation. Silver staining 
was performed to confirm successful pulldown. Trypsin digestion and mass spectrometry was 




2.13 Western Blotting and Antibodies 
Cell lysates were extracted with Sodium Dodecyl Sulfate(SDS)-Urea buffer. Samples were 
run on 10-15% SDS-PAGE gels, transferred to PVDF membrane and western blotting was 
performed using the following antibodies. BCL2 (BD Biosciences 551052), BCL2 (R&D 
Systems AF810), Bcl-XL (Cell Signaling 2764), MCL-1 (Cell Signaling 4572), GAPDH (), Actin 
(Sigma A2066), Tubulin (Millipore 05-829), Caspase-3 (Novus Biologicals MAB835), 
Asymmetric Dimethyl Arginine motif (Cell Signaling 13522S), Monomethyl Arginine motif (Cell 
Signaling 8015S), PRMT1 (Cell Signaling 2449), CARM1 (Cell Signaling 3379s), Phospho-
BLNK Tyr96 (Cell Signaling 3601), Phospho-SYK Tyr525/526 (Cell Signaling 2710), Phospho-
PLCγ2 Tyr759 (Cell Signaling 3874), Phospho-CD79A Tyr182 (Cell Signaling 5173), 
Phospho-SRC Family Tyr416 (Cell Signaling 6943), Phospho-BTK Tyr223 (Cell Signaling 
5082), Phospho-AKT Ser473 (Cell Signaling 9271), Phospho-AKT Thr308 (Cell Signaling 
2965), Total CD79A (Cell Signaling 3351), Phospho-CD19 Tyr531 (Cell Signaling 3571), Total 
CD19 (Bethyl A304-392A), Total SYK (Bethyl A300-559A), Total BTK (Novus MAB5807), 
Total AKT (Cell Signaling 9272), Total PLC2 (Novus MAB3716), Irf4 (Active Motif 61512), 
H4R3me2a (Active Motif 39705), H3R2me2a (Epigentek A-3714-050), H3K27me3 (Cell 
Signaling 9756), Total Histone H3 (Abcam AB1791), Total Histone H4 (Bethyl A300-646A), 
H3R17me2a (Active Motif 39710), H3K4me3 (Cell Signaling 9727), H3R26me2a (EMD 
Millipore 07-215), H3K36me2 (Active Motif 39256), H3K79me2 (Active Motif 39144), Pan-
Acetyl H3 (Active Motif 39140), H3K27ac (Active Motif 39136).   
2.14 In Vitro Methylation Assays 
Methylation assays were performed using recombinant GST-PRMT1 (BPS Biosciences 
51041) and recombinant FLAG-CARM1 (Active Motif 31347) purified from Sf9 cells. 
Recombinant PRC2 complex (His-EZH2/Flag-EED/His-SUZ12), His-GST-EZH2, and His-
FLAG-SUZ12 were also expressed in insect cells (BPS Biosciences 51003, 50279, 50282). 
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Nucleosome methylation assays used recombinant FLAG-CARM1 purified from HEK293 cells 
(BPS Biosciences 51047) and recombinant polynucleosomes derived from E. coli (Active 
Motif 31468). The assays used either PRC2 buffer (10X: 0.5M Tris pH 9.0, 5mM MgCl2, 4mM 
DTT) or PRMT1 buffer (10X Phosphate Buffered Saline pH 7.4). Radioactive assays were 








































3.1 Targeting BCR signaling to potentiate EZH2 inhibitor efficacy in DLBCL 
3.1.1 EZH2 inhibitor treatment increases global tyrosine phosphorylation and activates 
B-Cell Receptor signaling in lymphoma cells 
To determine whether there were any changes in intracellular kinase signaling after EZH2 
inhibitor treatment, we assessed tyrosine phosphorylation patterns in three cell lines with 
variable sensitivity to the EZH2 inhibitor EPZ-6438. All three cell lines display tonic B-Cell 
Receptor (BCR) signaling, which is necessary for SYK kinase-induced PI3K/AKT activation. 
H3K27 tri-methylation was effectively depleted after EZH2 inhibitor treatment (Figure 7a). 
Interestingly, two cell lines that were moderately sensitive (SUDHL-6) and resistant (SUDHL-
4) to EPZ-6438, showed a marked up-regulation in global tyrosine phosphorylation levels, 
while the hypersensitive cell line (SUDHL-10) showed an increase at lower doses but a 
negligible change at higher doses of the EZH2 inhibitor. High levels of global tyrosine 
phosphorylation in SUDHL-4 came from phosphorylation of key components of the BCR 
signaling pathway, such as SRC, SYK, CD79A, CD19, BLNK and PLC2 (Figure 7b). 
Interestingly, total CD79A levels also increased after EPZ-6438 treatment. Upon analysis of 
ChIP-Seq and gene expression data from a published study of the EZH2 inhibitor GSK126, 
we discovered that CD79A and SRC family kinases (SRC/HCK/LCK) are targets repressed 
by EZH2 in lymphoma cells (Figure 7c) (60). Although the lowest concentration of EPZ-6438 
was adequate to de-repress CD79A and increase its total protein level, phosphorylation of 
CD79A increased with higher concentrations of the inhibitor and correlated with SYK 
phosphorylation at Y525/526. BTK auto-phosphorylation at Y223 changed marginally. 
However, increased phosphorylation of its substrate PLC2 is an indicator of enhanced BTK 
activity in the context of SYK-induced BLNK phosphorylation. The involvement of different 
kinases and adaptor proteins in the BCR signaling pathway are shown for reference (Figure 
7d). Intriguingly, tonic BCR signaling involves only SYK-mediated AKT activation, and does 
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not involve BTK or PLC2. BTK activation upon EZH2 inhibitor treatment is indicative of an 
antigen-type BCR response, signifying a transformation of these cells to a centrocyte-like 













Figure 7. EZH2 inhibitor treatment enhances global tyrosine phosphorylation and BCR 
signaling. (a) Lymphoma cell lines SUDHL-10, SUDHL-6 and SUDHL-4 were treated with 
0.25, 0.5 and 1uM doses of EPZ-6438 for 6 days and changes in tyrosine phosphorylation 
were assessed using a pan-tyrosine phosphorylation (4G10) antibody. H3K27me3 was 
depleted in all three cell lines after EZH2 inhibitor treatment. (b) Before and after EPZ-6438 
treatment, SUDHL-4 cell lysates were analyzed for phosphorylation of key components of the 
BCR signaling pathway, including the SRC Family of Kinases (SFK), CD79A, CD19, SYK, 
BLNK, BTK and PLC2. (c) ChIP-Seq and gene expression data from a study of the EZH2 
inhibitor GSK126 was analyzed to identify BCR signaling pathway components that may be 
EZH2 targets in lymphoma cells (60). Results are represented as a Venn diagram. (d) 









3.1.2 Genetic Manipulation of BCR and CD19 augments EZH2 inhibitor efficacy 
To study the importance of BCR signaling after EZH2 inhibition, we analyzed EPZ-6438 
sensitivity of EZH2-mutant lymphoma cells engineered to delete the Hypervariable Region of 
the B-Cell Receptor (BCR-KO) using CRISPR/Cas9 technology (cell lines established by O 
Havranek and RE Davis). The moderately sensitive cell line SUDHL-6 was rendered 
hypersensitive to EPZ-6438 after BCR knockout, yielding a 44-fold shift in its IC50 value, from 
2.169uM to 0.049uM, at 7 days of treatment (Figure 8a). As a positive co-receptor of the BCR, 
CD19 lowers the threshold for BCR signaling, and acts as a molecular scaffold for multiple 
downstream regulators, most notably playing a role in PI3K activation. Therefore, we used 
SUDHL-6 cells with CD19 co-receptor knockout (CD19-KO) to assess whether CD19 was 
critical for sustaining BCR signaling in the absence of EZH2 activity. CD19-KO cells displayed 
a remarkable 271-fold shift in their IC50 value for EPZ-6438, from 2.169uM to 0.008uM, 
supporting the observation that BCR signaling becomes essential after inhibitor treatment. 
The sensitivity of CD19-KO cells to the inhibitor was still 6-fold higher than BCR-KO cells, 
suggesting that BCR-independent functions of CD19 may come into play and add to the role 
of this positive co-receptor post-EZH2 inhibition. Tonic BCR signaling is propagated by SYK, 
and primarily activates AKT to mediate cell survival. However, cells with PTEN-knockout do 
not depend on the BCR-SYK pathway to activate AKT. Accordingly, in the EZH2-wildtype cell 
line OCI-LY7, BCR-knockout renders it highly sensitive to EPZ-6438 treatment (0.025uM vs. 
0.441uM for BCR-KO vs. BCR-WT), but PTEN-knockout increases the EZH2 inhibitor IC50 
value to 0.095uM when combined with BCR-knockout (Figure 8b). On the other hand, the cell 
line DB, which is sensitive to EPZ-6438 and demonstrates little to no tonic BCR signaling, was 
only marginally affected by BCR-knockout (0.339uM vs 0.680uM for BCR-KO vs. BCR-WT), 
with a 2-fold shift in IC50 (Figure 8c). SUDHL-10 cells are PTEN-deficient with low BCR 
surface density, and are therefore not as dependent on tonic signaling as SUDHL-6 cells. 
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Interestingly, even though SUDHL-10 cells are already hypersensitive to EPZ-6438, they 
show a further shift in IC50 (3-fold) after BCR-knockout, from 0.377nM to 0.110nM. SUDHL-
7 and OCI-Ly8 cells, which are both EZH2-wildtype, displayed negligible changes in their IC50 
values for EPZ-6438 after BCR-knockout, and remained completely resistant to the inhibitor 
(Figure 8d). EPZ-6438 IC50 values for all the cell lines discussed above are displayed for 
comparison in Figure 8e. Together, these results support the hypothesis that signaling through 
the B-Cell Receptor, regardless of tonic or antigen type, sustains cell growth and survival in 
the aftermath of EZH2 inhibition in a subset of lymphoma cell lines. However, EZH2 
dependency may be a key factor in determining whether targeting BCR signaling can enhance 
response to the EZH2 inhibitor, since EZH2-wildtype cell lines originally lacking sensitivity to 
the inhibitor do not show any marked changes in sensitivity after BCR-knockout.  
 
3.1.3 Deficient tonic BCR signaling improves EZH2 inhibitor sensitivity  
Next, to assess the contribution of tonic BCR signaling specifically to the sensitizing effect of 
BCR-knockout in lymphoma cells, we used a GFP-fusion knock-in mutant of CD79A (Y188F) 
which blocks only tonic BCR signaling, but has no effect on active BCR signaling. CD79A 
becomes tyrosine phosphorylated at tyrosine residues in its ITAM domains upon BCR 
activation, enabling binding and activation of signaling mediators such as SYK kinase. In 
congruence with our observations in BCR-KO cells, the CD79A-Y188F mutant had no effects 
on EZH2 inhibitor sensitivity of the cell line DB, which demonstrates low levels of tonic 
signaling (Figure 8f). In SUDHL-6 cells, the Y188F mutant displayed a 7.6-fold shift in the IC50 
value for EPZ-6438 (0.144uM vs 1.098uM for CD79A-Y188F vs CD79A-WT). Differences 
between SUDHL-6 CD79A-WT and CD79A-Y188F cells after 8 days of EPZ-6438 treatment 
can be clearly observed through GFP imaging (Figure 8g). These results indicate that tonic 
BCR signaling via SYK and AKT at least partly contributes to the BCR-mediated response to 
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EZH2 inhibitor therapy. However, this phenomenon may be further reinforced by antigen-type 
BCR signaling, and provide a compensatory mechanism for cell growth and survival in the 









Figure 8. Genetic manipulation of components of the BCR signaling pathway 
potentiates sensitivity of lymphoma cells to the EZH2 inhibitor EPZ-6438. (a) EZH2-
mutant SUDHL-6 WT, BCR-KO and CD19-KO cells were treated with EPZ-6438 for 7 days 
and cell growth was measured using CellTiter-Glo viability assay. (b) Sensitivity to EPZ-6438 
treatment was determined in EZH2-wildtype OCI-Ly7 cells with PTEN-KO, BCR-KO or 
combined BCR and PTEN-KO (data generated by O Havranek and RE Davis). (c) EZH2-
mutant SUDHL-10 and DB cells with BCR-WT or BCR-KO were assessed for changes in 
proliferation after 7 days of EPZ-6438 treatment using CellTiter-Glo viability assay. (d) EZH2-
wildtype SUDHL-7 and OCI-Ly8 cells with wildtype-BCR or BCR-KO were treated with EPZ-
6438 for 7 days and analyzed using a similar method. (e) EPZ-6438 IC50 values for all cell 
lines described above are shown in tabular format. IC50 values were determined using 
Compusyn software. Shifts in IC50 value ≥ 2.0 are highlighted in red. (f) SUDHL-6 and DB 
cells expressing wildtype-CD79A or the Y188F mutant of CD79A were assessed for changes 
in cell proliferation after 7 days of EPZ-6438 treatment using CellTiter-Glo viability assay. IC50 
values are displayed in tabular format and a shift in IC50 value ≥ 2.0 is highlighted in red. (g) 
GFP fused to CD79A facilitated imaging of SUDHL-6 and DB CD79A-WT and CD79A-Y188F 
cells using an Incucyte Zoom instrument at 20X magnification after 8 days of Vehicle or EPZ-







3.1.4 EZH2 inhibitor-treated lymphoma cells exhibit an activated B-cell phenotype 
The threshold for BCR signaling is tightly controlled by co-receptors and their associated 
phosphatases. To assess if changes in BCR signaling were occurring as a result of 
imbalances in co-receptor expression, we analyzed cell surface expression of positive (CD19) 
and negative (CD22, CD72) co-receptors of the BCR, and the ligand for CD72 (CD100) in 
SUDHL-6 cells after EPZ-6438 treatment. We treated BCR-knockout and CD19-knockout 
cells alongside wildtype cells to be able to make a better comparison (Figure 9a). After 7 days 
of EZH2 inhibitor treatment, SUDHL-6 cells displayed increased CD19 and increased CD100 
expression (Figure 9b). There were no changes in CD72 (not shown) and IgM cell surface 
expression. Although the mean surface expression of CD22 marginally decreased after EPZ-
6438 treatment, there was a CD22-low population in the untreated condition that disappeared 
upon EZH2 inhibitor treatment. This was also seen in BCR-KO cells, but not in CD19-KO cells 
where the decrease in CD22 expression was more distinct than in the other two cell types. 
Interestingly, CD100 uniformly increased in all three types of SUDHL-6 cells after EPZ-6438 
treatment. Overall, these observed changes in co-receptor expression suggest that altered 
BCR signaling thresholds may at least partly contribute to aberrant activation of the BCR 
pathway after EZH2 inhibitor treatment. CD100 is a ligand belonging to the semaphorin family, 
which acts by switching off inhibitory signaling of the negative co-receptor CD72 and leading 
to SHP1 dissociation. CD72-CD100 ligation through B-cell:T-cell interactions are commonly 
associated with B-cell activation, and CD100 is sometimes expressed on the cell surface of 
activated B-cells themselves. SUDHL-6 cells pre-treated with EPZ-6438 demonstrate a robust 
proliferative response when stimulated with B-cell activating ligands such as CD40L and BAFF 
(Figure 9c). While EPZ-6438 treatment reduces SUDHL-6 cell growth by 30-40%, addition of 
CD40L or BAFF potently negates growth suppression by the EZH2 inhibitor. A similar 
phenomenon is observed in SUDHL-4 cells pre-treated with the EZH2 inhibitor. Since SUDHL-
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4 cells are resistant to the EZH2 inhibitor, there is a net increase in cell growth when EPZ-
6438 pre-treated cells are stimulated with CD40L. These results indicate that EZH2 inhibition 
promotes B-cell activation, and that the anti-proliferative effects of EPZ-6438 can be 












Figure 9. EZH2-mutant lymphoma cells show an Activated B-cell-like phenotype after 
EZH2 inhibition. (a) Flow cytometry was used to analyze CD19 and IgM cell surface 
expression after 7 days of EPZ-6438 treatment in SUDHL-6 cells with intact CD19 and IgM 
(WT), with IgM knockout (BCR-KO), or with CD19 knockout (CD19-KO). (b) CD19 and IgM 
cell surface expression are represented as histograms to visualize changes in the mean 
expression of these markers. In the same populations, cell surface expression of the negative 
co-receptor CD22 and the activating ligand CD100 (for the negative co-receptor CD72) was 
determined using flow cytometry. (c) Parental SUDHL-6 cells were pre-treated with vehicle or 
EPZ-6438 for 4 days and then inhibitor treatment was combined with CD40L or BAFF 
stimulation for another 3 days. Cell proliferation was assessed using CellTiter-Glo viability 










3.1.5 BCR-knockout cells demonstrate sustained CD19 signaling and PI3K/BTK 
dependency 
We studied the effects of BCR-knockout on SUDHL-6 cells to determine which signaling 
pathways were most affected by the absence of a functional BCR (Figure 10a). As expected, 
loss of tonic BCR signaling via SYK led to the depletion of both CD79A phosphorylation (Tyr-
182) and AKT phosphorylation (Ser-473). However, CD19 phosphorylation was notably higher 
in SUDHL-6 BCR-KO cells, and BTK displayed increased phosphorylation at a tyrosine 
residue (Tyr-551) targeted by LYN/SYK kinases. Accordingly, the BTK substrate PLC2 was 
increasingly phosphorylated in BCR-KO cells despite the absence of BCR signaling and lack 
of SYK activation. Interestingly, EZH2 inhibitor treatment in BCR-KO cells led to a reversal of 
PLC2 phosphorylation levels to that of control BCR-WT cells. This suggests that SUDHL-6 
BCR-KO cells maintain increased PLC2 phosphorylation through a mechanism that may 
depend on intact EZH2 activity. Combined with the loss of AKT activity, the inability of SUDHL-
6 BCR-KO cells to activate signaling downstream of BTK may be one of the reasons for their 
increased susceptibility to EZH2 inhibition. To assess the importance of BTK activation in 
these cells, we tested the effect of kinase inhibitors targeting PI3K and BTK in BCR-WT and 
BCR-KO cells (Figure 10b). SUDHL-6 BCR-KO cells were extremely sensitive to PI3K and 
BTK inhibition even at low doses, while their wildtype counterparts were resistant to the PI3K 






Figure 10. BCR-knockout cells display impaired CD79A signaling but maintain CD19 
signaling. (a) SUDHL-6 BCR-WT and BCR-KO cells were treated with EPZ-6438 at 2uM for 
48 hours and 72 hours. Cell lysates were collected and BCR signaling pathway components 
were analyzed for their phosphorylation status. (b) SUDHL-6 BCR-WT and BCR-KO cells 
were treated with varying doses of PI3K inhibitor (CAL101) or BTK inhibitor (PCI32765) for 
4 days and cell proliferation was measured using CellTiter-Glo viability assay. IC50 values for 
each inhibitor were determined using Compusyn software and displayed in table format.  
53 
 
3.1.6 Inhibitors of kinases downstream of BCR and CD19 show potent synergy in 
combination with EPZ-6438  
We used kinase inhibitors targeting three nodes of BCR signaling to assess rational 
combination therapies with the EZH2 inhibitor: the SYK inhibitor P505-15, the PI3Kinhibitor 
CAL101, and the BTK inhibitor PCI32765. SYK and PI3K inhibition would block both tonic 
and active BCR signaling, while BTK inhibition would selectively target active BCR signaling. 
SUDHL-6 and SUDHL-4, which display high levels of tonic BCR signaling, were both sensitive 
to combinations of EPZ-6438 and all three kinase inhibitors (SYK/PI3K/BTK). The SYK 
inhibitor is effective as a single agent in these two cell lines that rely on tonic BCR signaling, 
but even more effective when combined with the EZH2 inhibitor (Figure 11a). GCB-DLBCL 
cell lines are only sparingly sensitive to PI3K inhibition as a single agent, but become highly 
sensitive to CAL101 when combined with EPZ-6438 treatment (Figure 11b). The remarkable 
efficacy of PCI32765 in combination studies with EPZ-6438 suggests that BTK becomes 
highly relevant in the absence of EZH2 activity, while GCB-DLBCL cell lines generally do not 
respond to this inhibitor as a single agent (Figure 11c). The EZH2-wildtype cell line HT is 
moderately sensitive to EPZ-6438 due to a loss-of-function mutation in the H3K27 
demethylase KDM6A/UTX. Interestingly, it also lacks PTEN protein, leading to a high level of 
AKT activation. In this cell line, inhibitor combination studies showed significant synergy with 
the PI3K inhibitor and the BTK inhibitor. The EZH2-wildtype cell line SUDHL-5 was sensitive 
to PI3K inhibition in combination with EPZ-6438, despite being resistant to EZH2 inhibition 
as a single agent. In conclusion, we have showed that the EZH2 inhibitor synergizes with 
multiple inhibitors of kinases downstream of BCR signaling. Figure 11d is a model of 
‘targetable’ dependencies that could arise from EZH2 inhibitor treatment. Inhibitors targeting 
kinases in the BCR signaling pathway are in different stages of clinical trial for DLBCL, and 









Figure 11. The EZH2 inhibitor EPZ-6438 synergizes with SYK, PI3K and BTK inhibitors 
in lymphoma cell lines. (a) Combinations of the SYK inhibitor PRT062607 and EPZ-6438 
were analyzed at multiple constant ratios (1:1, 1:2, 1:4) in SUDHL-6, SUDHL-4, HT and 
SUDHL-5. Cells were pre-treated with the EZH2 inhibitor for 3 days, followed by 4 days of 
combined treatment with SYK and EZH2 inhibitors. Cell proliferation was measured using 
CellTiter-Glo viability assay, and combination indices were generated by Chou-Talalay 
analysis using Compusyn software. (b) A similar method was used for combinations of EPZ-
6438 and the PI3K inhibitor CAL101. (c) For combinations of the EZH2 inhibitor with the BTK 
inhibitor, ratios of 1:1, 1:4 and 1:8 were used for PCI32765 and EPZ-6438 respectively. Right, 
combination indices derived from different cell lines and inhibitors are provided in table format 
next to each panel. Dark red to yellow coloring marks CI values ranging from very highly 
synergistic (CI<0.1) to additive (CI between 0.9-1.1) at different doses of the inhibitors.  (d) A 
model illustrating targetable dependencies that may arise from EZH2 inhibitor treatment in 
lymphoma cells. When EZH2 activity is intact, GCB-DLBCL cells display tonic BCR signaling 
via PI3K/AKT, and are sensitive only to SYK inhibitors. However, lymphoma cells treated with 
the EZH2 inhibitor display both tonic and antigen-type BCR signaling, which makes them 






3.2 Type I PRMTs are novel and effective epigenetic targets in DLBCL 
3.2.1 Prolonged EZH2 inhibitor treatment increases global asymmetric di-methylation 
of histone H4 at arginine-3 
Suppression of EZH2 activity in lymphoma cells is expected to lead to global de-repression of 
its target genes and ‘rewiring’ of the epigenetic circuitry. Therefore, we examined global 
changes in histone modifications after prolonged EZH2 inhibitor treatment to assess if there 
were any epigenetic changes tightly associated with H3K27me3 depletion. 12 days of EPZ-
6438 treatment in SUDHL-6 and DB cells did not produce significant changes in most of the 
histone modifications that we profiled (Figure 12a). SUDHL-6 cells showed a significant 
increase in H3K36me2 levels, which is associated with MMSET activity. Interestingly, 
H3K4me3 levels were depleted and H4R3me2a levels were greatly enhanced after prolonged 
EPZ-6438 treatment. We analyzed H4R3me2a levels in multiple lymphoma cell lines after 
short-term EZH2 inhibitor treatment, and found that 5/6 cell lines showed a greater than 1.5-
fold enhancement in this modification (Figure 12b). DB cells did not display a change in 
H4R3me2a at 4 days of treatment, but showed a distinct increase in this modification after 
longer durations of treatment.  There was no correlation between EZH2 mutation status, 
sensitivity to the EZH2 inhibitor, and fold-change in H4R3me2a levels. We wanted to 
determine whether the increase in H4R3me2a was indicative of a favorable response to the 
EZH2 inhibitor, or whether it was involved in protecting lymphoma cells against the effects of 
EZH2 inhibition. PRMT1 is the major arginine methyltransferase known to catalyze the 
H4R3me2a modification. PRMT1-specific inhibitors are not available, but a Type I inhibitor 
called MS023 can effectively deplete H4R3me2a in different cell types (120). Therefore, we 
used MS023 in combination with EPZ-6438 to assess whether Type I PRMT inhibition can 
enhance the growth-suppressive effect of EZH2 inhibition or perhaps block these suppressive 
effects. When combined, EPZ-6438 and MS023 significantly increased apoptotic cell death in 
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DB and SUDHL-5 cells, while neither of them induced apoptosis as a single agent (Figure 
12c). Co-treatment with EPZ-6438 and MS023 synergistically controlled cell growth in four 
lymphoma cell lines: DB, SUDHL-5, HT and RL (Figure 12d). Interestingly, RL and SUDHL-5 
are EZH2-mutant and EZH2-wildtype respectively, but both are resistant to EPZ-6438 
treatment. In SUDHL-6 cells, the Type I PRMT inhibitor MS023 as a single agent was far more 
effective than the combination treatment, and astonishingly superior to the EZH2 inhibitor 
alone. Similarly, the lymphoma cell line RL was also highly sensitive to MS023 as a single 
agent. These observations prompted us to investigate whether Type I PRMT inhibition as a 
single agent may have therapeutic potential in the treatment of DLBCL. To understand the 
mechanism behind MS023 and EPZ-6438 synergy, we first had to study the role of Type I 











Figure 12. EZH2 inhibitor treatment increases global Histone H4 Arginine-3 asymmetric 
di-methylation and synergizes with the Type I PRMT inhibitor MS023 in lymphoma cells. 
(a) SUDHL-6 and DB cells were treated with EPZ-6438 for 12 days. Cell lysates were 
analyzed for changes in multiple histone modifications including H3K4me3, H3R17me2a, 
H3K36me2, H3K79me2, H3-acetyl (pan), H4R3me2a, and H3K27me3. Fold-change in 
histone marks are represented as a graph. (b) Pfeiffer, SUDHL-6, DB, SUDHL-5, HT and 
SUDHL-4 cells were treated with EPZ-6438 for 4 days. H4R3me2a, pan-acetyl histone H3, 
H3K27me3 and total histone H4 levels were assessed. Fold-change is represented in 
graphical format. EZH2-mutant cell lines are colored in red and EZH2-wildtype cell lines are 
colored in blue. (c) DB, SUDHL-5 and HT cells were co-treated with 1uM MS023 and 2uM 
EPZ-6438 for 8 days and the percentage of apoptotic cells was measured using Active 
Caspase-FITC staining coupled with flow cytometry. Statistical significance was calculated 
using 2-way ANOVA (p<0.05*) (d) DB, SUDHL-5, SUDHL-4, HT, and RL cell lines were co-
treated with MS023 and EPZ-6438 for 8 days at a constant ratio of 1:2. Cell growth was 
measured using CellTiter-Glo viability assay, and combination indices were generated by 
Chou-Talalay analysis using Compusyn software. Combination indices are displayed in 
tabular format. Synergistic values (CI<0.9) are highlighted in red, and additive values (CI 0.9-





3.2.2. Type I PRMT inhibition suppresses cell growth and viability in a subset of DLBCL 
cell lines 
In a panel of DLBCL cell lines, Type I PRMT inhibition using MS023 led to a significant 
reduction in the number of viable cells after 7 days of treatment (Figure 13a). The cell lines 
RL, Toledo, SUDHL-6, SUDHL-4, SUDHL-7 and DB were highly sensitive to MS023, with 
IC50 values less than 1uM. Considering that many of these cell lines are EZH2-mutant, it is 
interesting to note that RL, SUDHL-6 and SUDHL-4 have much lower IC50 values for MS023 
in comparison to EPZ-6438. The ABC-DLBCL cell lines U-2932 and HBL-1, and the EZH2-
wildtype cell lines SUDHL-5 and HT, were less sensitive to the Type I PRMT inhibitor with 
IC50 values greater than 1uM. Next, we performed cell cycle analysis for RL, SUDHL-4 and 
DB after 7 days of MS023 treatment (Figure 13b). DB and SUDHL-4 displayed G1-phase cell 
cycle arrest, while RL displayed a less marked difference. We also quantified the percentage 
of apoptotic cells after 7 days of MS023 treatment in RL, SUDHL-6 and DB cells (Figure 13c). 
For RL and SUDHL-6, there was a distinct increase in the percentage of apoptotic cells by 
active caspase staining. On the other hand, DB showed negligible changes in apoptosis after 
inhibitor treatment. Using COSMIC Cell Lines project and cBioPortal, we looked for mutations 
in epigenetic regulators among the DLBCL cell lines used in our study (Figure 13d) (46, 47, 
127). Cell lines that were highly sensitive to MS023 harbored mutations in multiple epigenetic 










Figure 13. The Type I PRMT inhibitor MS023 induces cell cycle arrest and apoptosis in 
a panel of lymphoma cell lines. (a) DLBCL cell lines were treated with varying doses of 
MS023 for 7 days and cell growth was measured using CellTiter-Glo viability assay. IC50 
values were calculated from MS023 dose-response curves using nonlinear regression 
analysis in GraphPad Prism, and these values are represented in table format to the right of 
the graph. (b) Propidium iodide staining and flow cytometry was used to determine cell cycle 
staging in RL, SUDHL-4 and DB cells after MS023 treatment for 7 days. Data analyzed using 
ModFit LT 5.0 software is displayed in both graphical and tabular format. (c) After 8 days of 
MS023 treatment, the percentage of apoptotic cells in RL, SUDHL-6 and DB was quantified 
using Active Caspase-FITC staining and flow cytometry. Statistical significance was assessed 
using 2-way ANOVA and the Bonferroni method (p<0.01** and p<0.001***). (d) Using data 
from COSMIC Cell Lines project and cBioPortal, the lymphoma cell lines utilized in our study 
were examined for alterations in the most frequently mutated epigenetic enzymes (46, 47, 








3.2.3 MS023 treatment reduces BCL2 levels to induce apoptosis in sensitive lymphoma 
cells 
Many DLBCL cell lines harbor genomic amplification of the BCL2 locus or a t(14;18) 
chromosomal translocation leading to BCL2 overexpression (Figure 14a). To identify 
mechanisms contributing to apoptosis in cell lines sensitive to MS023, we screened for 
changes in key apoptosis mediators. This revealed a distinct reduction in the level of anti-
apoptotic BCL2 protein after MS023 treatment in all cell lines tested (Figure 14b). Interestingly, 
the cell lines that underwent cell death upon Type I PRMT inhibition were previously reported 
to be BCL2-dependent cell lines with high sensitivity to the BCL2 antagonist ABT-199 
(Venetoclax) (87). Protein levels of PRMT1, CARM1 and PRMT6 did not show any significant 
correlations with BCL2 levels across different cell lines. After 72 hours of MS023 treatment, 
BCL-XL levels did not change appreciably. In DB and HT cells, MCL-1 protein levels increased 
after PRMT inhibition, presumably as a compensatory mechanism after BCL2 loss. 
Interestingly, DB and HT are both reported to be MCL-1-dependent cell lines, even though 
DB has high BCL2 levels arising from a t(14;18) chromosomal translocation (128). While 
asymmetric arginine methylation was predictably depleted at a global level after MS023 
treatment, changes in histone methylation marks unique to different PRMTs gave us a hint 
about the primary target of the inhibitor that leads to BCL2 loss. PRMT1 activity was 
significantly suppressed by the inhibitor, as seen from near complete depletion of H4R3me2a 
levels. However, CARM1/PRMT4 and PRMT6 inhibition was insufficient and variable across 
different cell lines, as evidenced by residual levels of H3R17me2a and H3R2me2a 
respectively. This observation prompted us to question whether PRMT1 was the primary 





3.2.4 PRMT1 regulates BCL2 in DLBCL cell lines 
Using inhibitors specific to different Type I PRMTs, we analyzed changes in BCL2 protein 
levels in the cell line HT (Figure 14c). None of the inhibitors which targeted PRMT3, PRMT4/6 
or PRMT6 alone were able to modulate BCL2 levels. A global increase in Mono-Methyl 
Arginine (MMA) is indicative of effective PRMT1 inhibition (112). BCL2 levels were only 
reduced by the two inhibitors that could target PRMT1: MS023 and IACS-013355. In RL cells, 
at higher concentrations of the PRMT6 inhibitor EPZ020411, we could observe a decrease in 
the BCL2 level (Figure 14d). This correlated with an increase in global MMA, which is in 
agreement with published reports that EPZ020411 has off-target effects on PRMT1 and 
PRMT8 at higher concentrations of the inhibitor. Therefore, we hypothesized that the change 
in BCL2 was a result of PRMT1 inhibition. Using siRNA specific to PRMT1, we knocked down 
PRMT1 expression in two BCL2-dependent DLBCL cell lines RL and Toledo, and examined 
changes in cell viability and BCL2 protein levels. PRMT1 knockdown reduced cell viability by 
40% and 60% in RL and Toledo cells respectively (Figure 14e). PRMT1 knockdown in RL 
cells led to a decrease in BCL2 levels and completely depleted histone H4R3 asymmetric di-
methylation (Figure 14f). From these observations, we concluded that MS023 mediated its 










Figure 14. MS023 decreases levels of anti-apoptotic BCL2 protein in DLBCL cell lines 
through efficient PRMT1 inhibition. (a) Lysates from multiple lymphoma cell lines were 
blotted for protein levels of BCL2, PRMT1, CARM1 and PRMT6. Cell lines were grouped 
according to BCL2 amplification and translocation status. (b) DLBCL cell lines were treated 
with MS023 for 72 hours and cell lysates were blotted for apoptosis regulators like BCL2, BCL-
XL and MCL-1. Histone arginine methylation marks associated with PRMT1, CARM1 and 
PRMT6 activity were also assessed. (c) HT cells were treated with inhibitors specific to 
different PRMTs at 2uM concentration for 96 hours. Lysates were collected and blotted for 
asymmetric arginine di-methylation, mono-methylation and BCL2. (d) RL cells were treated 
with different PRMT inhibitors at 5uM concentration for 96 hours and assayed for changes in 
arginine methylation and BCL2. (e) PRMT1 was knocked down using two different siRNA in 
BCL2-dependent RL and Toledo cell lines. Changes in cell viability after 4 days of siRNA 
treatment were determined using the CellTiter-Glo viability assay. Statistical significance was 
assessed using 2-way ANOVA (p<0.01** and p<0.001***). (f) Lysates were collected from RL 
cells treated with PRMT1 siRNA for 96 hours. Western blotting was performed to examine 







3.2.5 Type I PRMT inhibition modulates BCL2 at the transcriptional level 
In RL cells, ectopically expressed BCL2 was unaffected by MS023 treatment, indicating that 
BCL2 regulation may occur at the transcriptional level and involve the native promoter of BCL2 
(Figure 15a). Additionally, ectopic BCL2 expression partially protected RL cells from apoptosis 
induced by PRMT inhibitor treatment, as indicated by reduced caspase-3 cleavage. Using 
qRT-PCR, we showed that BCL2 mRNA was reduced by 50% upon MS023 treatment in RL 
and SUDHL-6 cells (Figure 15b). Next, we performed Chromatin Immunoprecipitation (ChIP) 
in RL cells to assess H4R3me2a deposition in the promoter region of BCL2 (Figure 15c). 
Compared to the IgG control, there was an 8-fold enrichment of H4R3me2a in the BCL2 
promoter region. This result supports the idea that the PRMT1 inhibitor MS023 down-
regulates BCL2 by blocking its transcriptional activation (Figure 15d). In this way, MS023 







Figure 15. MS023 regulates BCL2 at the transcriptional level. (a) Ectopic expression of 
BCL2 in RL cells was followed by inhibitor treatment for 72 hours. Lysates were collected and 
blotted for BCL2, myc-tag and caspase-3 cleavage. (b) RL cells were treated with MS023 for 
72 hours, RNA was extracted and analyzed by qRT-PCR using primers against BCL2 and 
GAPDH (control). Statistical significance was determined using a two-tailed unpaired t-test 
(p<0.0001**** and p<0.001***). (c) RL cells were fixed with formaldehyde, sonicated and 
subjected to chromatin immunoprecipitation using antibodies against H4R3me2a and isotype 
control (IgG). Primers against BCL2 and GAPDH promoter regions were used to amplify DNA 
fragments, followed by qPCR. (d) A model illustrating the role of PRMT1 in regulating 
mitochondrial apoptosis in lymphoma cells. PRMT1 activates anti-apoptotic BCL2 at the 




3.2.6 PRMT1 is overexpressed in DLBCL tumors and correlates with poor prognosis 
Using gene expression data from Oncomine, we analyzed PRMT1 expression in normal B-
cells and DLBCL patient tumors from two independent cohorts (Figure 16a) (129-131). The 
mean expression of PRMT1 was 1.95-fold and 1.93-fold higher in tumor cells compared to 
their normal counterparts, and the difference was statistically significant (p<0.0001****) for 
both cohorts. Next, we determined whether PRMT1 expression levels may relate to overall 
survival in patients with DLBCL (Figure 16b-d). With the help of three different datasets 
extracted from Oncomine, we first established the optimal cutoff for each dataset using 
KaplanScan (132-134). Then, we plotted Kaplan-Meier curves using the individual cutoff 
values, with patients assigned to ‘High’ or ‘Low’ expression categories based on expression 
values above or below the cutoff respectively. In all datasets that were examined, high PRMT1 
expression correlated with poor overall survival in patients, and the p-values were statistically 
significant. These results support the idea that PRMT1 may play an important role in DLBCL 



























Figure 16. PRMT1 is overexpressed in DLBCL tumors and correlates with poor overall 
patient survival. (a) Using two different datasets from Oncomine, ‘Brune Lymphoma’ and 
‘Basso Lymphoma’, PRMT1 expression in normal B-cells and lymphoma cells from patients 
was analyzed and statistical significance was determined using a two-tailed t-test 
(p<0.0001****). (b) Using the dataset ‘Shipp Lymphoma’ to analyze overall patient survival, 
PRMT1 expression cutoffs were calculated with the help of the software KaplanScan and 
patients were divided into low PRMT1-expressing and high PRMT1-expressing categories. 
Statistical differences in overall patient survival between the two categories were determined 
by the Log-rank method (p<0.05*). (c) A similar method was used to analyze overall patient 
survival in ‘Lenz Lymphoma’ and statistical differences were determined by both Log-rank 
method (p<0.01**) and Gehan-Breslow-Wilcoxon method (p<0.01**). (d)  For ‘Rosenwald 
Lymphoma’, a similar method was used for overall patient survival, and statistical analysis 








3.2.7 Arginine methylation of CD79A does not play a role in the lymphoma cell response 
to EPZ-6438 and MS023 
In normal B-cells, PRMT1 was previously reported to methylate CD79A at R204, leading to 
altered downstream B-Cell Receptor signaling through SYK and AKT. Since we observed 
synergy between EPZ-6438 and MS023 in multiple lymphoma cell lines, and we have showed 
that BCR signaling blockade sensitizes cells to the EZH2 inhibitor, we analyzed whether 
arginine methylation of CD79A might contribute to this phenomenon. Using SUDHL-6 and DB 
cells expressing an arginine methylation-resistant mutant of CD79A (R204K), we assayed for 
EPZ-6438 sensitivity of mutant cells compared to wildtype-CD79A expressing cells (Figure 
17a). There was no significant change in the EZH2 inhibitor sensitivity of both SUDHL-6 and 
DB cells expressing the R204K mutant. Additionally, we examined whether MS023 exerted 
any of its anti-proliferative or apoptotic effects by modulating BCR signaling. We achieved this 
by assessing the MS023 dose-response of BCR-WT and BCR-KO cells (Figure 17b). Again, 
BCR-knockout did not significantly affect MS023 sensitivity in both SUDHL-6 and DB cells. 
From these results, we can conclude that arginine methylation of CD79A is not likely to play 















Figure 17. Arginine methylation of CD79A is not an important mediator of the response 
to MS023 and EPZ-6438 in lymphoma cells. (a) SUDHL-6 and DB cells expressing CD79A 
with an R204K mutation were assessed for their response to 7 days of EPZ-6438 treatment, 
and compared to cells expressing wildtype-CD79A. (b) SUDHL-6 and DB cells with BCR-
knockout were exposed to varying doses of MS023 for 7 days and cell proliferation was 









3.3 Physical and functional interactions between EZH2, PRMT1, and CARM1 
3.3.1 Mass Spectrometry reveals novel EZH2-interacting proteins in cancer cells 
To identify novel EZH2 interacting proteins, we immunoprecipitated myc-tagged EZH2 from 
MCF7 breast cancer cells and performed mass spectrometric analysis. This yielded a 
comprehensive list of potential interacting partners. When ranked according to the signal ratio 
of EZH2 immunoprecipitate compared to the isotype control immunoprecipitate, the top hits 
were core and accessory components of the PRC2 complex: SUZ12, AEBP2, JARID2, and 
PHF1. Other PRC2 components such as PHF19, EED, RBBP7 and RBBP4 were ranked lower 
in the list due to background signal in the control sample. For the other hits, we categorized 
proteins based on their functions, and focused mainly on enzymes (kinases, phosphatases, 
methyltransferases, ubiquitin ligases, deubiquitinases) for further study. Interestingly, the 
arginine methyltransferases PRMT1 and CARM1 were identified as EZH2 interacting proteins. 
Although they were not highly ranked, this may be a result of weak or transient interactions 




















1 Q15022 Polycomb protein SUZ12 SUZ12 22107000 0 ∞ 20 46 
2 Q6ZN18 Zinc finger protein AEBP2 AEBP2 8363500 0 ∞ 11 34 
3 Q92833 Protein Jumonji JARID2 6648100 0 ∞ 14 18 




PAPSS2 2538800 0 ∞ 8 17 
6 Q06830 Peroxiredoxin-1 PRDX1 2437350 0 ∞ 4 28 
7 P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 2230050 0 ∞ 2 18 
8 O43189 PHD finger protein 1 PHF1 1933750 0 ∞ 5 20 
9 Q8N5D0 WD and tetratricopeptide repeats protein 1 WDTC1 1871200 0 ∞ 10 19 
10 O15042
U2 snRNP-associated SURP motif-
containing protein
U2SURP 1604950 0 ∞ 5 6 
11 Q9P1Y6
PHD and RING finger domain-containing 
protein 1
PHRF1 1558200 0 ∞ 4 4 
12 P24666
Low molecular weight phosphotyrosine 
protein phosphatase
ACP1 1461950 0 ∞ 3 25 
13 P24468 COUP transcription factor 2 NR2F2 1351100 0 ∞ 3 8 
14 O00241 Signal-regulatory protein beta-1 [CD172b] SIRPB1 1265950 0 ∞ 2 7 
15 O00361 P40 ORF1 1167700 0 ∞ 4 17 
16 P35241 Radixin RDX 1046600 0 ∞ 5 13 
17 O95782 AP-2 complex subunit alpha-1 AP2A1 1010330 0 ∞ 9 13 
18 P62995 Transformer-2 protein homolog beta TRA2B 1001420 0 ∞ 4 16 
19 Q00577 Transcriptional activator protein Pur-alpha PURA 894195 0 ∞ 2 15 
20 Q9NRA8
Eukaryotic translation initiation factor 4E 
transporter
EIF4ENIF1 715250 0 ∞ 5 11 
21 Q6AI08 HEAT repeat-containing protein 6 HEATR6 708815 0 ∞ 4 5 
22 Q5T6S3 PHD finger protein 19 PHF19 708210 0 ∞ 5 11 
23 P10155 60 kDa SS-A/Ro ribonucleoprotein TROVE2 696520 0 ∞ 2 8 
24 Q7Z404 Transmembrane channel-like protein 4 TMC4 665960 0 ∞ 2 4 
25 Q13427 Peptidyl-prolyl cis-trans isomerase G PPIG 661715 0 ∞ 2 3 
26 P62857 40S ribosomal protein S28 RPS28 639735 0 ∞ 3 52 
27 Q9NYL9 Tropomodulin-3 TMOD3 614640 0 ∞ 3 13 
28 P63092
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short
GNAS 578465 0 ∞ 3 6 
29 P09382 Galectin-1 LGALS1 573680 0 ∞ 2 22 
30 O60313 Dynamin-like 120 kDa protein, mitochondrial OPA1 531700 0 ∞ 4 6 
31 P00558 Phosphoglycerate kinase 1 PGK1 469445 0 ∞ 2 8 
32 Q92616 Translational activator GCN1 GCN1L1 426625 0 ∞ 3 2 
33 O00311 Cell division cycle 7-related protein kinase CDC7 412365 0 ∞ 2 3 
34 Q9UK61 Protein FAM208A FAM208A 408355 0 ∞ 6 6 
35 Q9P2M7 Cingulin CGN 371255 0 ∞ 4 5 
36 P16989 Y-box-binding protein 3 YBX3 357890 0 ∞ 3 25 
37 O15231 Zinc finger protein 185 ZNF185 342750 0 ∞ 2 7 
38 Q96A33 Coiled-coil domain-containing protein 47 CCDC47 327470 0 ∞ 2 5 
39 Q99569 Plakophilin-4 PKP4 256935 0 ∞ 2 2 
40 Q8NHV4 Protein NEDD1 NEDD1 254810 0 ∞ 2 6 
41 P51659 Peroxisomal multifunctional enzyme type 2 HSD17B4 250935 0 ∞ 3 6 
42 P35606 Coatomer subunit beta' COPB2 226825 0 ∞ 3 3 
43 Q7Z5K2 Wings apart-like protein homolog WAPAL 222535 0 ∞ 3 5 
44 Q9NZC9
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily 
A-like protein 1
SMARCAL1 217405 0 ∞ 3 3 
















Trinucleotide repeat-containing gene 6A 
protein




DUS3L 167495 0 ∞ 2 5 
48 P28290 Sperm-specific antigen 2 SSFA2 158608 0 ∞ 2 2 
49 Q14573 Inositol 1,4,5-trisphosphate receptor type 3 ITPR3 153010 0 ∞ 2 1 
50 Q9NTI5
Sister chromatid cohesion protein PDS5 
homolog B




UGGT1 92704 0 ∞ 2 2 
52 Q15910 Histone-lysine N-methyltransferase EZH2 EZH2 76772000 77995 984 26 55 
53 O75530 Polycomb protein EED EED 73774000 259190 285 26 64 
54 Q14764 Major vault protein MVP 7554750 54645 138 21 34 
55 O75165 DnaJ homolog subfamily C member 13 DNAJC13 6742600 61855 109 33 21 
56 O60216
Double-strand-break repair protein rad21 
homolog
RAD21 8470650 221760 38 17 43 
57 Q9NYF8 Bcl-2-associated transcription factor 1 BCLAF1 4.31E+08 12555000 34 3 40 
58 P06396 Actin-depolymerizing factor Gelsolin GSN 8189200 243920 34 14 32 
59 Q08380 Basement membrane autoantigen p105 LGALS3BP 38215000 1288450 30 17 39 
60 Q92624
Amyloid beta precursor protein-binding 
protein 
APPBP2 18453000 627700 29 15 33 
61 Q6ZRI8 Rho GTPase-activating protein 36 ARHGAP36 7101500 252025 28 10 28 
62 Q9Y2W1
Thyroid hormone receptor-associated 
protein 3
THRAP3 4.57E+08 16447500 28 44 37 
63 Q8NEY8 Gastric cancer antigen Ga50 PPHLN1 3290850 119050 28 3 7 
64 Q99590 CTD-associated SR protein 11 SFRS2IP 16787500 676305 25 22 24 
65 P51116
Fragile X mental retardation syndrome-
related protein 2
FXR2 8576450 355200 24 13 38 
66 Q6ZRV2 Protein FAM83H FAM83H 4952300 244780 20 11 16 
67 P84090 Enhancer of rudimentary homolog ERH 7206800 425170 17 6 55 
68 Q2I5I4 Four and a half LIM-domain protein 2 FHL2 31677500 1903150 17 15 49 
69 Q13303 K(+) channel subunit beta-2 KCNA2B 1.8E+08 11098500 16 1 66 




GAPDH 1.08E+08 7303850 15 17 71 
72 F5H012 Tripartite motif-containing protein 21 TRIM21 29155500 2099750 14 19 39 
73 Q9H329
Erythrocyte membrane protein band 4.1 like 
4B variant
EPB41L4B 18629000 1356900 14 13 35 
74 Q9UQE7 Structural maintenance of chromosomes 3 SMC3 8056350 587685 14 22 23 
75 Q15149 Plectin-1 PLEC1 2.57E+08 19045000 13 190 48 
76 Q16576 Histone-binding protein RBBP7 RBAP46 3491900 276030 13 4 20 
77 Q9Y3Y2 Chromatin target of PRMT1 CHTOP 29053500 2751000 11 5 26 
78 P27694 Replication factor A protein 1 REPA1 1.65E+08 15682000 11 45 78 
79 Q14683
Structural maintenance of chromosomes 
protein 1A
SMC1A 8659450 850275 10 31 32 
80 Q5VTI5
Pleckstrin homology domain containing, 
family A member 6
PLEKHA6 661990 65210 10 6 10 
81 Q5VWN6 Uncharacterized protein C10orf18 C10orf18 6323050 645940 10 15 8 
82 Q13573 Nuclear receptor coactivator NCoA-62 SNW1 4997700 514150 10 2 5 
83 P35244 Replication factor A protein 3 REPA3 9704350 1026710 9 3 38 
84 P15927 Replication factor A protein 2 REPA2 21976000 2498450 9 11 64 
85 Q14498 RNA-binding motif protein 39 RBM39 9100500 1051300 9 13 35 
86 P19387 DNA-directed RNA polymerase II subunit C POLR2C 1570700 181585 9 7 43 
87 Q09028 Histone-binding protein RBBP4 RBAP48 6901850 799245 9 3 14 
88 Q15654 Thyroid receptor-interacting protein 6 TRIP6 8276500 1011630 8 9 27 
89 Q99873 Protein arginine N-methyltransferase 1 PRMT1 45628500 5930500 8 23 60 




Table 1. EZH2-associated proteins in MCF7 cells identified through Mass Spectrometry. 
Myc-tagged EZH2 was immunoprecipitated from MCF7 breast cancer cells and interacting 
proteins were identified by mass spectrometry. This table lists only proteins that are more than 
4-fold enriched compared to the isotype control. Proteins are ranked based on the signal ratio 
of EZH2 immunoprecipitate compared to control immunoprecipitate (EZH2/C). Core and 
accessory components of the PRC2 complex are highlighted in yellow.  













91 P26196 ATP-dependent RNA helicase p54 DDX6 84645000 14177500 6 28 72 
92 P50851 CDC4-like protein CDC4L 754855 126715 6 6 3 
93 Q96QE5 UPF0629 protein C17orf42 C17orf42 1638300 285115 6 6 22 
94 Q9BY49 Peroxisomal trans-2-enoyl-CoA reductase PECR 38369000 6706950 6 15 56 
95 P24928 DNA-directed RNA polymerase II subunit A POLR2A 13390500 2346250 6 31 22 
96 P55884
Eukaryotic translation initiation factor 3 
subunit B
EIF3B 4120900 732855 6 12 20 
97 P30876 DNA-directed RNA polymerase II subunit B POLR2B 6283450 1123950 6 25 30 
98 P51114
Fragile X mental retardation syndrome-
related protein 1
FXR1 36917000 6942150 5 7 48 
99 P04792 Heat shock 27 kDa protein HSP27 32687000 6233400 5 8 66 
100 Q70EL4 Ubiquitin-specific-processing protease 43 USP43 1179650 225920 5 7 12 
101 Q9BYD3 39S ribosomal protein L4, mitochondrial MRPL4 20029500 4172800 5 10 47 
102 Q9Y6J9
TAF6-like RNA polymerase II p300/CBP-
associated factor-associated factor 65 kDa 
subunit 6L
TAF6L 2838050 608065 5 6 18 
103 Q06787 Fragile X mental retardation 1 protein FMR1 33417500 7262000 5 1 56 
104 O60573
Eukaryotic translation initiation factor 4E type 
2
EIF4E2 2955600 643405 5 5 26 
105 Q9UH62
ARM protein lost in epithelial cancers on 
chromosome X 3
ALEX3 13639000 2992100 5 12 44 
106 Q14966 Zinc finger protein 638 ZNF638 6515050 1545100 4 21 14 
107 Q13045 Protein flightless-1 homolog FLII 1053675 259020 4 10 11 
108 Q15437 Protein transport protein Sec23B SEC23B 310420 77580 4 1 3 
109 Q86V97
Kelch repeat and BTB domain-containing 
protein 6
KBTBD6 16016500 4095600 4 14 57 
110 Q9NWH9 Modulator of estrogen-induced transcription MET 2058350 533500 4 8 10 
111 Q8N539 Fibrinogen C domain-containing protein 1 FIBCD1 12338000 3208850 4 9 36 
112 Q96QR8 Transcriptional activator protein Pur-beta PURB 1635050 428165 4 4 30 
113 Q86X55 Histone-arginine methyltransferase CARM1 PRMT4 8786350 2317000 4 7 16 
114 Q96NB2 Sideroflexin-2 SFXN2 3915200 1035250 4 5 19 
115 P07384 Calcium-activated neutral proteinase 1 CANPL1 2830850 750855 4 12 22 
116 Q59G16 BRG1-associated factor 170 BAF170 179825 48666.5 4 2 4 
117 P40429 60S ribosomal protein L13a RPL13A 1711650 473410 4 3 18 
118 P00338 L-lactate dehydrogenase LDHA 1904850 529835 4 5 15 
119 P50542 Peroxin-5 PEX5 3989900 1118100 4 15 42 
120 P68104 Elongation factor 1-alpha 1 EEF1A 1.34E+08 37727000 4 15 46 
121 Q8N4Q0
Zinc-binding alcohol dehydrogenase domain-
containing protein 2
ZADH2 24600500 6989150 4 12 38 
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3.3.2 PRMT1 and CARM1 methylate components of the PRC2 complex in vitro 
Since EZH2, PRMT1 and CARM1 are methyltransferases, we wanted to know if they could 
modify each other at the post-translational level. We performed in vitro methylation assays 
using the core PRC2 complex (EZH2/SUZ12/EED) and either PRMT1 or CARM1, in the 
presence of tritiated S-Adenosylmethionine (SAM) (Figure 18a). We also used two different 
buffers (PRC2 and PRMT1), to maintain optimal enzymatic activity of the PRC2 complex and 
PRMT1 respectively as their names suggest, while both buffers work well for CARM1. The 
strongest methylation signal came from a protein at 90kDa, in the reaction containing PRC2 
and CARM1. This protein could be either EZH2 or SUZ12, since both proteins have similar 
molecular weights. There was also a weaker methylation signal in the PRMT1/PRC2 reaction 
at the same molecular weight. Finally, there was a weak signal at the molecular weight 
corresponding to EED in both PRC2/PRMT1 and PRC2/CARM1 reactions, but only when 
PRMT1 buffer was used. From these observations, we can conclude that EZH2 cannot 
methylate PRMT1 or CARM1. However, it appears that PRMT1 and CARM1 can methylate 
PRC2 complex components in vitro. 
To identify if the methylation signal at 90kDa came from SUZ12 or EZH2, we performed 
individual methylation reactions using recombinant SUZ12 and EZH2 protein (Figure 18b,c). 
PRMT1 was able to methylate SUZ12 alone, but not EZH2. CARM1 was unable to methylate 
EZH2 or SUZ12 alone, but could strongly methylate one or both of them as part of an intact 
PRC2 complex. Next, we used an antibody that recognizes asymmetric di-methylarginine 
motifs (ADMA) to detect methylation by PRMT1/CARM1 in immunoprecipitated PRC2 
complexes after in vitro methylation reactions (Figure 18d). We performed the methylation 
reaction, immunoprecipitated PRC2 complex proteins, and performed stringent washes to 
remove the associated PRMT1/CARM1. PRMT1 easily disengaged from the PRC2 complex, 
but CARM1 remained strongly bound, leading to the presence of a strong CARM1 auto-
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methylation signal in the eluate. Interestingly, the post-immunoprecipitation washes showed 
no presence of methylated CARM1, indicating that 100% of auto-methylated CARM1 
associated with the PRC2 complex. Methylation of EZH2/SUZ12 by CARM1 could be detected 
by the ADMA antibody. Interestingly, methylation of EED by PRMT1 was recognized by this 


































Figure 18. PRMT1 and CARM1 can methylate PRC2 complex members in vitro. (a) 
Methylation reactions were performed with recombinant EZH2/SUZ12/EED, combined with 
either PRMT1 or CARM1, and tritiated SAM. Two different buffers were used to facilitate 
optimal enzymatic activity of all components. (b) SUZ12 alone was used as a substrate for 
PRMT1 and CARM1 and similar methylation reactions were performed. Reactions performed 
under similar conditions with the PRC2 complex are included as a reference. (c) EZH2 alone 
was utilized as a substrate for PRMT1 and CARM1. (d) In vitro methylation was performed 
with PRC2 complex and PRMT1/CARM1. His-tagged EZH2 and SUZ12 were 
immunoprecipitated using Talon resin and PRMT1/CARM1 was washed away. The eluate 
was analyzed for asymmetric arginine di-methylation with an antibody that can recognize 









3.3.3 PRMT1 and CARM1 co-immunoprecipitate with the PRC2 complex in vivo 
We used Duolink Proximity Ligation assays to assess co-localization of EZH2 with PRMT1 
and CARM1. EZH2 and PRMT1 showed significant co-localization in MCF7 breast cancer 
cells (Figure 19a). However, we were not able to detect CARM1/EZH2 co-localization using 
this assay. This might be a technical issue arising from antibody-epitope recognition. When 
we co-transfected HA-PRMT1 and the PRC2 component Flag-EED into 293T cells, we found 
that the interaction between PRMT1 and EED was detectable but weak (Figure 19b). This 
suggests that they may form part of a larger complex or that their interaction may not be strong 
enough to be maintained during conventional immunoprecipitation procedures. Interestingly, 
an enzyme-dead mutant of PRMT1 (E171Q) also interacted with EED to the same extent as 
the wildtype enzyme. Interactions between endogenous CARM1 and Flag-tagged EED were 
detectable in 293T cells, without the need for CARM1 overexpression (Figure 19c). In the 
context of PRMT1 overexpression, EED associated with an arginine-methylated protein that 
migrated at the same molecular weight as CARM1 and showed a similar expression pattern. 
3.3.4 Nucleosome methylation by PRC2/CARM1 and PRC2/PRMT1 complexes 
Using nucleosome methylation assays, we found that PRMT1 did not markedly affect histone 
H3K27 methylation by the PRC2 complex in vitro (Figure 19d). Surprisingly, the PRC2 
complex promoted histone H4R3 asymmetric di-methylation by PRMT1. This phenomenon 
did not require the histone H4-binding accessory PRC2 component RbAp48. The core PRC2 
complex consisting of EZH2, SUZ12, and EED was adequate for facilitating H4R3 methylation 
by PRMT1.   
CARM1 strongly methylates Histone H3R17 and weakly methylates Histone H3R26 in vitro. 
Both of these modifications are involved in transcriptional activation. H3R26 methylation by 
CARM1 is predicted to block H3K27 methylation by PRC2, although this has not been 
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conclusively shown in literature. H3R17 methylation is also expected to block PRC2 activity, 
in a manner similar to other active marks like H3K4me3 and H3K36me2. Addition of PRC2 to 
a CARM1-containing nucleosome methylation reaction reduced both H3R17me2a and 
H3R26me2a signals, but dramatically increased the H3K27 tri-methylation signal (Figure 
19e). Surprisingly, PRC2 and CARM1 together yielded a much higher H3K27me3 signal than 
PRC2 alone. This was unexpected, because CARM1 has never been shown to influence 
H3K27 methylation, especially in a positive way. Addition of PRMT1 to a CARM1-containing 
reaction increased arginine di-methylation of CARM1. This methylation activity may come 
from PRMT1-mediated methylation of CARM1 or from CARM1 auto-methylation. The latter is 
more likely since the reaction was performed in PRC2 buffer, and we have previously showed 
that this buffer is not optimal for PRMT1 activity. Another interesting observation from this 
experiment was that recognition of CARM1 by an antibody that binds to an epitope 























Figure 19. Interactions between PRC2, PRMT1, and CARM1 may influence their 
enzymatic activities. (a) In MCF7 cells, Duolink Proximity Ligation assay was performed to 
detect interactions between PRMT1 and EZH2. (b) In 293T cells, Flag-tagged EED was co-
transfected with wildtype or enzyme-dead (E171Q) HA-tagged PRMT1, and EED was 
immunoprecipitated with Flag-M2 beads. The eluate was blotted for PRMT1, Flag-tag, EZH2 
and SUZ12. (c) Flag-tagged EED was immunoprecipitated from 293T cells co-expressing 
HA-PRMT1, and the eluate was blotted for ADMA and CARM1. An ADMA signal 
corresponding to the molecular weight of CARM1 was detected.  (d) Nucleosome 
methylation reactions were performed with PRMT1, the core PRC2 complex, and PRC2 
complex combined with RbAp48. Histone H4R3me2a and H3K27me3 levels were 
determined. (e) Nucleosome methylation reactions were performed with recombinant PRC2 
complex, CARM1, and PRMT1/CARM1 together. Reaction samples were assayed for 





























4.1 Targeting kinases downstream of BCR to improve the therapeutic response to EZH2 
inhibitors 
SUDHL-6 BCR-knockout and CD19-knockout cells demonstrated remarkable hypersensitivity 
to EZH2 inhibition with EPZ-6438. This big shift in IC50 suggests that BCR/CD19 signaling 
may provide a compensatory mechanism that supports cell survival after EZH2 ablation. 
Based on this observation, we combined EPZ-6438 with inhibitors of kinases downstream of 
BCR, specifically targeting SYK, BTK and PI3K. Although BTK was not expected to play a 
role in tonic BCR signaling, PCI32765 was able to sensitize lymphoma cells to EPZ-6438 
treatment. PI3K is adequate to maintain tonic BCR signaling, and therefore PI3K inhibition 
was not expected to have much of an effect either. Surprisingly, inhibitors targeting all three 
kinases (SYK, PI3K and BTK) greatly synergized with EPZ-6438 in SUDHL-6, SUDHL-4 and 
HT cells. In the case of the PI3K inhibitor CAL101, this was especially striking, because 
single-agent treatment yielded insignificant effects on the growth of GCB-DLBCL cell lines 
when used at low doses. The BTK inhibitor PCI32765 is known to have off-target effects at 
higher concentrations, and this can be seen clearly when it is used as a single-agent. 
However, when combined with EPZ-6438, its IC50 value dropped to a range that correlates 
with on-target efficacy in ABC-DLBCL cells. The SYK inhibitor PRT062607 has considerable 
anti-proliferative effects as a single-agent, and these effects are greatly potentiated by EPZ-
6438 addition. These results support a critical role for the BCR signaling pathway after EZH2 
inhibitor therapy. The contribution of BTK to this phenomenon suggests combined 
involvement of tonic and antigen-type BCR signaling. However, there is no antigen available 
to promote BCR ligation in these cells, and neither do they harbor mutations in BCR signaling 
elements. Therefore, the possible origin of antigen-type BCR signaling in these cells 
represents an interesting question. An imbalance in negative and positive co-receptors may 
greatly lower the threshold for BCR activation and allow enhanced downstream signaling. To 
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investigate this hypothesis, we analyzed cell surface expression of CD19, CD22, CD72, and 
its ligand CD100. CD100 was the only marker that consistently increased in lymphoma cells 
after EPZ-6438 treatment. Increased CD100 expression may decrease SHP-1 activity in these 
cells by switching ‘off’ inhibitory co-receptor signaling by CD72. This could lead to amplified 
and sustained BCR signaling in EPZ-6438-treated lymphoma cells. It would be interesting to 
determine whether CD100 knockdown could sensitize lymphoma cells to the EZH2 inhibitor 
and partially block BCR signaling. Another possible reason for altered tyrosine kinase 
signaling is co-opting of the BCR by another receptor which can be activated by secreted 
ligands in the media. EZH2 is a well-known repressor of cytokine genes, and therefore, EPZ-
6438 treatment may induce these cells to release cytokines and activate cytokine receptors 
(135).  
SUDHL-6 cells without functional BCR and CD19 are viable, but display a slightly slower 
growth rate. To understand how these cells can survive in the absence of tonic BCR signaling, 
we tested multiple kinase inhibitors and found that BCR-KO cells were highly sensitive to both 
BTK and PI3K inhibition. Upon dissection of downstream signaling pathways, we noticed that 
CD19 phosphorylation was greatly increased in BCR-KO cells. This suggests that CD19 
activation can occur independently of the BCR. This is not surprising, because CD19 has 
previously been implicated in PI3K/AKT activation that occurs independently of BCR/CD79A 
signaling (136). BTK is phosphorylated at Y551 to a greater extent in BCR-KO cells, and 
phosphorylation of its substrate PLC2 is observed. Y551 phosphorylation performed by either 
SYK or LYN kinase, is not necessarily indicative of BTK activation, and phosphorylation of its 
substrate is a more reliable indicator of its activity. Therefore, in this case, PLC2 
phosphorylation in BCR-KO cells signifies BTK activation through a BCR-independent 
mechanism, and PI3K activation downstream of CD19 may be responsible for this 
phenomenon. However, the depletion of AKT phosphorylation in BCR-KO cells confirms that 
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AKT is dependent on tonic BCR signaling and SYK activation, and cannot be maintained by 
BCR-independent CD19 signaling. Considering that both AKT and BTK require PIP3 
generation by PI3K to become activated, it is interesting to consider why AKT activity is 
dependent on BCR and SYK, but BTK activity is not.  
Tonic BCR signaling can occur through either PI3K or PI3K, while active BCR signaling is 
uniquely reliant on PI3K (11). Considering the increased dependence on PI3K in BCR-KO 
cells, it is possible that the involvement of specific PI3K isoforms may influence the extent of 
BTK activation. Interestingly, AKT negatively regulates BTK signaling by phosphorylating it at 
two sites, promoting its sequestration by the 14-3-3 family of proteins, and consequently 
leading to its degradation. There is a possibility that enhanced BTK stability in the absence of 
AKT contributes to its increased activity. There are still many questions that remain 
unanswered. BLNK phosphorylation by SYK is required to bring BTK and PLC2 together, 
and it is not clear how this occurs in BCR-KO cells without SYK activity. The mechanism 
behind EZH2 inhibitor sensitivity of BCR-KO and CD19-KO cells warrants further 
investigation. EZH2 inhibitor treatment reduces BTK phosphorylation at Y551 and depletes 
PLC2 phosphorylation in BCR-KO cells. This suggests that the compensatory mechanisms 
sustaining SUDHL-6 cells in the absence of BCR and CD19 function are inadequate for 
maintaining cell survival and growth upon EZH2 ablation. 
To summarize, our study demonstrates striking synergy between EZH2 inhibitors and kinase 
inhibitors targeting SYK, PI3K, and BTK. Although the mechanism requires more detailed 






4.2 PRMT1 plays an important role in DLBCL before and after EZH2 inhibitor therapy  
At the histone level, EZH2 inhibitor treatment wipes out H3K27 tri-methylation and induces 
de-repression of EZH2 target genes. Many of these genes are related to B-cell differentiation 
(IRF4, BLIMP1), cell-cycle progression (CDNK1A, CDKN2A), and apoptosis (BCL2) (5). EZH2 
inhibition checks the uncontrolled growth of lymphoma cells by pushing them along a path to 
terminal differentiation. Increased histone acetylation at early time points (4 days) after 
inhibitor treatment is an indicator of EZH2 target gene re-activation. Histone acetylation is 
often preceded by histone methylation mediated by a variety of lysine and arginine 
methyltransferases. After 12 days of EPZ-6438 treatment, there was a slight increase in 
H3K36me2 upon H3K27me3 depletion, which correlates with reports of the antagonistic 
nature of these two marks. The existence of H3K36 methylation impedes H3K27 methylation 
by PRC2 in cis (137). Therefore, it is possible that the converse is also true.  
The relationship between H3K27 methylation and histone arginine methylation is not well-
studied, even though hints from in vitro studies suggest that CARM1-mediated H3R26 
methylation may block H3K27 methylation. In vivo, H3R26me2a is a low abundance mark 
which is not detectable in lymphoma cells (unpublished data). In our experiments, we found 
that EZH2 inhibition led to a substantial increase in Histone H4 Arginine-3 asymmetric di-
methylation across multiple cell lines, regardless of EZH2 mutation status. H4R3me2a is a 
mark of transcriptional activation, prompting us to question whether increased PRMT activity 
is a positive mediator of EZH2 inhibitor sensitivity. PRMTs have previously been linked to both 
promotion and blockade of cell differentiation. In neuronal cells, PRMT1 and PRMT8 regulate 
retinoic acid-induced differentiation (138). In hematopoietic stem cells, PRMT4/CARM1 
methylates Runx1 to block their differentiation into myeloid progenitors (104).   
We questioned whether Type I PRMT-mediated H4R3 di-methylation was instrumental in 
promoting terminal differentiation after EZH2 inhibitor treatment. Surprisingly, we found that 
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while Type I PRMT inhibition blocked the expression of differentiation-related genes like IRF4 
in SUDHL-6 and Pfeiffer cells (unpublished data), it improved sensitivity to EZH2 inhibitor 
treatment in other cell lines like RL, DB, HT and SUDHL-5. In SUDHL-6 cells, PRMT inhibitor 
treatment displayed potent growth-suppressive effects as a single-agent, and EZH2 inhibitor 
addition did not produce additivity or synergy. To better understand the effects of PRMT 
inhibition, we tested the pan-Type I PRMT inhibitor MS023 as a single-agent in DLBCL cell 
lines. MS023 treatment prompted cell death in BCL2-dependent lymphoma cell lines, such as 
SUDHL-6, RL and Toledo. Apoptosis induction was minimal in cell lines known to be MCL1-
dependent (HT, SUDHL-4, SUDHL-5) or dependent on neither MCL1 nor BCL2 (DB) (128). 
However, MS023 still induced anti-proliferative effects in these cell lines, and promoted cell-
cycle arrest in DB and SUDHL-4. Using siRNA to dissect the contribution of different PRMTs, 
we showed that BCL2 down-regulation by MS023 was mediated by PRMT1.  
PRMT1 has distinct functions in the cytoplasm and in the nucleus. Cytoplasmic functions of 
PRMT1 in B-cells are not well-studied. However, PRMT1 can methylate CD79A associated 
with the pre-BCR at Arginine-204 and deregulate signaling via SYK and PI3K/AKT. In our 
experiments, we did not observe any changes in EZH2 inhibitor sensitivity of SUDHL-6 and 
DB cells expressing CD79A with an R204K mutation, making it resistant to PRMT1-mediated 
arginine methylation. Additionally, we did not observe any shifts in the IC50 for MS023 in both 
SUDHL-6 and DB cells lacking the BCR, suggesting that MS023 does not mediate its 
apoptotic or growth-suppressive effects through altered BCR signaling. Therefore, we can 
conclude that CD79A arginine methylation by PRMT1 does not play a role in the response to 
EZH2 inhibitor treatment and is not involved in mediating the therapeutic effects of MS023. 
Despite the potent effects of MS023 on BCL2 and apoptosis induction as a single-agent, we 
found that the cell lines responding well to combination therapy with MS023 and EPZ-6438 
were not BCL2-dependent.  Favorable responses to the combination also did not correlate 
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with the fold-increase in H4R3me2a after EZH2 inhibitor treatment. For example, DB and 
SUDHL-5 showed minimal changes in H4R3me2a at 8 days after EPZ-6438 treatment, but 
showed maximal synergy with MS023 treatment. Therefore, mechanisms contributing to 
inhibitor synergy remain under investigation. 
Our study shows that PRMT1 is a promising target for the treatment of GCB-DLBCL, and adds 
to the list of epigenetics-based therapies in lymphoma, including EZH2, BET bromodomain, 
and HDAC inhibitors. DLBCL is characterized by mutations in multiple epigenetic regulators 
such as EZH2, KMT2D/2C, CREBBP and EP300, with a distinct shift in favor of global 
transcriptional repression. Co-occurrence of epigenetic mutations may create transcriptional 
vulnerabilities in lymphoma cells. CREBBP/EP300 mutations co-occur with inactivating 
mutations in KMT2D in 40% of DLBCL cases. Additionally, one functional allele of 
CREBBP/EP300 is always maintained, and concurrent inactivation of both histone 
acetyltransferases is rarely observed in the same tumor (43). Based on these observations, it 
has been suggested that CREBBP-mutant lymphoma cells may be ‘addicted’ to EP300 
histone acetyltransferase activity. This hypothesis could be easily tested using newly available 
CREBBP/EP300 inhibitors (139). In our study, we have showed that Type I PRMT inhibitors 
potently suppress lymphoma cell growth and viability. Like KMT2D, CREBBP and EP300, 
PRMT1 also plays an important role in transcriptional activation via H4R3me2a deposition. It 
is possible that PRMT1 and KMT2D/CREBBP/EP300 have common target genes, and 
perhaps PRMT1 activity represents an additional vulnerability for lymphoma cells with 
mutations in these epigenetic regulators. Further examination is required to determine if there 
is any relationship between mutations in KMT2D/CREBBP/EP300 and PRMT1 inhibitor 
sensitivity. To summarize, our study demonstrates an important role for PRMT1 in DLBCL, 




4.3 Interactions of PRC2 with PRMT1 and CARM1 may influence histone H4R3 and 
H3K27 methylation 
When we first identified PRMT1 and CARM1 as potential binding partners of EZH2 in MCF7 
breast cancer cells, we wanted to investigate if they could methylate each other. Initial 
experiments using EZH2 alone with PRMT1/CARM1 yielded negative results. However, when 
we used the critical core components of the PRC2 complex (EZH2/SUZ12/EED), we observed 
methylation of a protein at 90kDa by both PRMT1 and CARM1. Due to similar molecular 
weights, this created multiple possibilities: that either EZH2, or SUZ12, or both of these 
proteins can be methylated by PRMT1 and CARM1. Next, we used SUZ12 alone as a 
substrate and observed that it could be methylated by PRMT1. It is very interesting that neither 
EZH2 nor SUZ12 can be methylated as solo substrates by CARM1, although the signal at 
90kDa is very strong when the PRC2 complex is used as a substrate. This may occur because 
complex formation changes the structural conformation of the substrate to expose the relevant 
arginine residues for methylation by CARM1. Previously, we have noticed that when individual 
components of the PRC2 complex are expressed separately, purified from insect cells and 
then mixed together in a reaction, the resulting complex is not as effective at catalyzing 
H3K27me3, compared to a complex that is derived from simultaneous expression of all three 
components (unpublished data).  
An antibody recognizing the asymmetric dimethylarginine motif was able to recognize 
methylation of EZH2/SUZ12 by CARM1 when the PRC2 complex was immunoprecipitated 
after performing in vitro methylation reactions. This antibody could not recognize SUZ12 
methylation by PRMT1, but interestingly, it detected a weakly methylated protein at 50kDa. 
Considering the high purity of the recombinant proteins used, there is a significant possibility 
that this signal corresponds to EED methylation. Next, we performed nucleosome methylation 
assays to assess whether the interactions of PRMT1/CARM1 with PRC2 might differentially 
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modulate their catalytic activities towards histone substrates. Remarkably, we noticed that the 
PRC2 complex enhanced histone H4R3 methylation by PRMT1. This activity did not require 
the presence of the accessory PRC2 component RbAp48 which binds to Histone H4. Since 
PRMT1 cannot directly bind to DNA, we suspect that the PRC2 complex may act as a ‘bridge’, 
by improving its access to histone H4 to perform methylation. PRMT1 did not significantly 
affect H3K27 methylation activity of the PRC2 complex. 
Unexpectedly, CARM1 enhanced H3K27 tri-methylation by the PRC2 complex. This result 
was astonishing, because CARM1 methylates histone H3 at arginine-26 in vitro, which is 
supposed to block H3K27 tri-methylation. In our experiment, both H3R17 and R26 methylation 
by CARM1 was reduced in the presence of the PRC2 complex, and H3K27me3 was the 
predominant histone modification observed. Addition of PRMT1 to a reaction containing 
CARM1 and PRC2 did not affect H3K27me3, but increased the arginine di-methylation signal 
on CARM1. If PRMT1 increases auto-methylation of CARM1, it is possible that a site different 
from the well-documented R550 site may be undergoing methylation. Interestingly, 
PhosphositePlus indicates that amino acid R49 may undergo arginine methylation (140). The 
CARM1 antibody used in our studies recognizes an epitope surrounding R49. Therefore, if 
PRMT1 promotes CARM1 auto-methylation at R49, it might affect the antibody’s ability to 
recognize the epitope. Since we used the same antibody to perform the Duolink Proximity 
Ligation Assay, it may well explain why there was no detectable interaction between EZH2 
and CARM1. Accordingly, EED immunoprecipitated from cells with PRMT1 overexpression 
were found to associate with an arginine-methylated protein that migrated at the same 
molecular weight as CARM1. Additional experiments have to be performed to confirm that 
CARM1 can be methylated at arginine-49. Since R49 is in the N-terminal domain of CARM1 
that assumes a PH-like superfold, it might play an important function in substrate recognition. 
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It is unclear how PRMT1 might regulate CARM1 methylation activity, and the significance of 
increased H3K27 tri-methylation by PRC2 in the presence of CARM1 is also not clear. We 
suspect that this enhancement of PRC2 methylation activity by CARM1 may not be involved 
in transcriptional repression, but play a role in alternative mRNA splicing. H3K27me3 has 
recently been linked to alternative splicing, and PRMTs have extensively been associated with 
regulation of mRNA splicing (141). It is important to note that the recombinant CARM1 used 
for in vitro methylation assays with PRC2 was extracted from insect cells and highly pure, but 
the CARM1 used in nucleosome methylation assays was derived from HEK293 cells and 
relatively less pure. Therefore, we remain cautious about contaminating proteins that may be 
mediating H3K27me3 enhancement in these assays. Further studies are required to confirm 
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